

adipogenic differentiation compared to non-induced MSC. However, the comparison of MSCs cultured in the presence of HTLV-1 and the MSC control culture revealed no significant difference in the mRNA expression of the *PPAR- γ* gene (Fig. 4II).

To further evaluate the effect of HTLV-1 infection on osteogenesis, we compared MSC control cultures and MSCs exposed to HTLV-1. The osteogenic differentiation potential of MSCs was not altered by HTLV-1, and the analyses of calcium deposition and mineralization of the extracellular matrix indicated that there were no significant differences in osteogenic differentiation potential of the studied samples (Fig. 4D, F, H, and J). The analysis of the mRNA expression of the runt-related transcription factor 2 (*RUNX2*) gene revealed that this gene was 2.4-fold overexpressed in MSCs undergoing differentiation into osteocytes than in non-differentiated MSC. However, the *RUNX2* expression level in MSCs that had contact with HTLV-1 was similar to that found in the MSC control culture, indicating that HTLV-1 does not alter the differentiation potential of MSCs into osteocytes (Fig. 4III). These results suggest that HTLV-1 does not modify the differentiation potential of MSCs into adipocytes and osteocytes.

MSCs are susceptible to HTLV-1 infection

Because HTLV-1 infects various cell types, we questioned whether MSCs are susceptible to HTLV-1 infection *in vitro*. First, we evaluated the expression of genes encoding proteins for HTLV-1 receptors, such as *GLUT1*, *HSPG*, and *NRP1*. These gene products are involved in the initial interaction between the cell and the virus and are required for HTLV-1 infection in different cell types. MSCs isolated from the BM of healthy individuals exhibited a *GLUT1* gene expression level similar to that obtained in CD4⁺ T cells from healthy individuals and CD4⁺ T cells from HTLV-1-infected individuals; however, the *HSPG* gene was overexpressed (37-fold) in MSCs compared with CD4⁺ T cells from HTLV-1 individuals ($p=0.0022$). The expression level of the *NRP1* gene was 11-fold higher in CD4⁺ T cells from HTLV-1 individuals compared with CD4⁺ T cells from healthy individuals ($p=0.004$); however, *NRP-1* presented higher expression levels in MSCs (Fig. 5).

To evaluate whether the contact of HTLV-1 with MSCs allows the efficient infection of MSCs, we investigated the presence of HTLV-1 provirus in DNA samples extracted from MSCs exposed to HTLV-1. We observed the amplification of the HTLV-1 *Tax* gene by PCR only in MSCs that were cultured with irradiated MT2 cells. No amplification was observed in MSCs grown with cell-free

HTLV-1 particles and in the MSC control cultures (Fig. 6I). The results obtained by PCR corroborated the analyses of the expression levels of HTLV-1 proteins. As shown in Fig. 6II (E and F), MSCs cultured with MT2 cells are positive for the HTLV-1 p19 protein, as evidenced by confocal microscopy analyses (Fig. 6III and 6IV). No evidence of the p19 specific signal was observed in the control cultures (Fig. 6IIH and III). The HTLV-1 Tax regulatory protein was also detected in MSCs co-cultured with MT2 cells by flow cytometry, which suggests that HTLV-1 results in productive infection and viral replication in MSCs (Fig. 6IV).

Discussion

HTLV-1 is a retrovirus that primarily infects T cells and is able to establish lifelong latency in its host. Although the great majority of HTLV-1-infected individuals remain asymptomatic, a minor group of patients develops one of two main disorders, namely HAM/TSP and ATLL, and other clinical manifestations, such as uveitis, arthritis, and infectious dermatitis (Oh and Jacobson, 2008; Yoshida et al., 1984; LaGrenade et al., 1990; Mariette et al., 2000). Various factors, such as the proviral load and the effectiveness of the immune response, are considered important factors that determine the risk of developing clinical diseases (Manns et al., 1999; Montanheiro et al., 2005).

In contrast, the immunomodulation properties of MSCs can exert an effective inhibitory effect on the function of immune cells and thus provide an interesting therapeutic tool for the treatment of degenerative disorders, as well as inflammatory and autoimmune diseases (Di Nicola et al., 2002; Bartholomew et al., 2002). Several studies have reported that the role of MSCs can be modulated by inflammatory mediators released from activated immune cells (Waterman et al., 2010; Auletta et al., 2012). Thus, the exposure of MSCs to an infectious or inflammatory micro-environment could alter their functions and change their differentiation potential and interaction with immune cells.

In this study, we present data that demonstrate the influence of HTLV-1 on the biological and functional features of BM-derived MSCs. Our results showed that MSCs exposed to HTLV-1 display distinct characteristics from those of MSCs cultured under control conditions. For example, contact with HTLV-1 resulted in the accumulation of vesicles in the cytosol of MSCs, and this phenomenon is similar to that observed when HTLV-1 infects HeLa cells, Jurkat cells, and human primary PBMCs (autophagic vacuoles). This accumulation of autophagosomes is induced by the HTLV-1 Tax protein and benefits virus replication (Tang et al., 2013).

Surface molecules, such as ICAM-1, VCAM-1, and HLA-DR, were found to be upregulated in MSCs after contact with HTLV-1. In addition, PBMCs isolated from HTLV-1 symptomatic individuals were also able to modulate the expression of VCAM1 and HLA-DR in MSCs, even without direct cell contact.

The cell surface glycoproteins ICAM-1 and VCAM-1 are members of the immunoglobulin superfamily that are closely related to the processes of recognition, interaction, and adhesion. The expression of ICAM-1 and VCAM-1 first occurs in endothelial cells and immune system cells; however, previous studies have described that MSCs may produce large amount of chemokines and adhesion molecules after stimulation with inflammatory cytokines (Ren et al., 2008, 2010). Moreover, the serum of HAM/TSP individuals shows a higher concentration of pro-inflammatory cytokines, such as TNF- α , IL-6 and IFN- γ , compared with that of asymptomatic individuals, and these cytokines can modulate the MSC adhesion molecules (Starling et al., 2013). Other studies have shown that MSC activity can be modulated differently depending on the environment. Viral infections are stimuli that can enhance the immunosuppressive capacity promoted by MSCs due to an increase in the expression of




Fig. 5. Gene expression of HTLV-1 receptors in different cell types. Quantification by real-time PCR of the mRNA levels of *GLUT1*, *HSPG*, and *NRP-1* in CD4⁺ T cells and MSCs isolated from healthy individuals and HTLV-1-infected individuals. The data are reported as expression relative units (ERU) and represent the means \pm SEM of triplicate experiments. We used a one-tail Mann-Whitney *t* test, and the asterisks denote significant differences compared with CD4⁺ T cells (* $p < 0.05$ and ** $p < 0.01$).




Fig. 6. HTLV-1 infection in MSCs. (I) Human β -globin and HTLV-1 tax gene amplification by PCR. The results were obtained from three independent experiments. Control mesenchymal stromal cells (MSC01, MSC02, and MSC03), MSCs cultured with cell-free HTLV-1 particles (MSC01+virus, MSC02+virus, and MSC03+virus), and MSCs cultured in the presence of irradiated MT2 cells (MSC01+MT2, MSC01+MT2, and MSC01+MT2), MT2 DNA (positive control), and no template control (NTC). (II) Representative immunofluorescence staining of mesenchymal stromal cells. (A) MSCs co-cultured with MT2 cells were stained with DAPI (blue) and (B) anti-CD73 (red); (C) overlap of DAPI (blue) and anti-CD73 (red) staining. MSCs co-cultured with MT2 cells were stained with (D) DAPI (blue) and (E) anti-CD19 (green); (F) overlap of DAPI (blue) and anti-CD19 (green) staining. The nucleus of control MSCs were stained with (G) DAPI (blue) and (H) anti-CD19 (green); (I) overlap of DAPI (blue) and anti-CD19 (green) staining. The scale bars represent 10 μ m. (III and IV) Representative flow cytometry dot plots of MSCs co-cultured with MT2 cells. (III) Isotype-matched control antibodies. (IV) The dots in the upper right quadrant of the flow plot represent cells that coexpress CD73 and the HTLV-1 tax protein (8%).

adhesion molecules (ICAM-1 and VCAM-1) (Ren et al., 2010). Therefore, MSCs exposed to HTLV-1 should also induce a differentiated immunosuppressive effect on T lymphocytes because ICAM-1 and VCAM-1 expression modulate the immune regulatory properties of MSCs.

According to the literature, a significant increase in the expression levels of ICAM-1 (CD54) and LFA-3 (CD58) has been described in MSCs in response to CMV infection, and this increase is associated with a higher adherence of hematopoietic cells to CMV-infected MSCs (Smirnov et al., 2007). Previous studies have demonstrated that, in HTLV-1 infection, ICAM-1 and LFA-1 are modulated in T cells (Barnard et al., 2005), and these interactions

are important for cell fusion and the dissemination of HTLV-1, thereby allowing an improvement of the cell-cell contact, the polarization of the cytoskeleton, and the formation of a viral synapse (Igakura et al., 2003). However, the increased expression of adhesion molecules (ICAM-1 and VCAM-1) in MSCs exposed to HTLV-1 suggests that the contact between infected cells and MSCs is favored and may also promote the HTLV-1 infection of MSCs and BM resident cells.

With respect to the expression of HLA-DR, some researchers have shown that the expression of HLA-DR in MSCs depends on the IFN- γ concentration. Upon exposure to antigens, the initial doses of IFN- γ induce the expression of MHC-II molecules and

thereby facilitate the antigen presenting properties of MSCs. However, at high levels of IFN- γ , the MHC-II expression is down-regulated, which causes a loss in the ability of MSCs to act as antigen presenting cells (APCs) (Stagg et al., 2006; Romieu-Mourez et al., 2007).

Other typical surface molecules that are commonly used in the characterization of MSC, such as CD271 and CD13, were also modulated by HTLV-1 contact. However, further studies should be conducted to understand the differences in the expression of these molecules in MSCs exposed to HTLV-1 because no studies have reported the involvement of CD271 in virus infection and CD13 expression is considered important in other infections, e.g., in CMV infection, CD13 is reported to act as a receptor (Soderberg et al., 1993).

The functional capacity of MSCs to differentiate into adipocytes and osteocytes was not altered in MSCs exposed to HTLV-1, and this finding was confirmed by the analysis of the gene expression levels of PPAR γ and RUNX-2. Previous reports have described that HTLV-1 may be linked to bone alteration by increasing the population of active osteoclasts in ATLL patients (Kiyokawa et al., 1987). This change is likely not related to HTLV-1-exposed MSCs because we observed that HTLV-1 did not impair the osteogenic differentiation potential of this cell population. It is believed that the alterations observed in the osteoclasts of ATLL cells and HTLV-1-infected T cells maintained in culture may arise due to the overexpression and secretion of specific cytokines that stimulate the proliferation of osteoclast precursors and promote their differentiation (Tendler et al., 1991).

Other authors who assessed the MSC differentiation potential during HIV infection showed that the p55-gag viral protein affects osteogenesis by reducing calcium deposition and the expression and activity levels of RUNX-2. However, the cell lipid levels and PPAR γ activity were increased by HIV proteins during adipogenic MSC differentiation (Cotter et al., 2008, 2011, 2007). Experiments performed with sera from high-viral-load HIV-infected individuals induced a proadipogenic phenotype, as evidenced by the increased adipocyte formation and the expression of PPAR γ (Cotter et al., 2011). HIV infection has also been found to affect the proliferation and osteogenic differentiation of MSCs isolated from Tg26 HIV-1 mice, which suggests that the infection progressively causes damage to MSC functionality (Cheng et al., 2013).

Our results also provide the first demonstration that the interaction between HTLV-1 and BM-derived MSCs leads to their infection *in vitro*. In fact, the presence of HTLV-1 integrated provirus was evidenced only in MSCs that had direct contact with an infected cell and not with cell-free virions, which shows that direct contact with an infected cell is efficient for the virus infection of MSCs. These findings support the hypothesis that the main transmission route for HTLV-1 infection first occurs through cell-to-cell contact because cell-free virions are very poorly infectious *in vitro* (Donegan et al., 1994). However, in other cell types, such as DCs, efficient and productive infection has been observed with cell-free HTLV-1 (Jones et al., 2008).

The existence of HTLV-1-infected cells in the BM had been explored in *in vivo* studies on ATLL patients, and the results have shown that HTLV-1 DNA is detected in BM mononuclear cells but not in hematopoietic stem cells (CD34⁺) (Nagafuji et al., 1993). An extensive latent infection in the BM of patients with HTLV-1 has also been demonstrated; however, the phenotype of HTLV-1-infected BM cells is unclear (Jacobson et al., 1997). We suggest the biological existence of HTLV-1-infected MSCs in the BM of HTLV-1-infected individuals; however, further studies are necessary to detect the productive infection of MSCs isolated from HTLV-1-infected individuals.

Others studies have previously been performed to elucidate the susceptibility of MSCs to virus infection and the possible consequences of the contact of MSCs with infectious agents. Herpes virus (HSV-1) was found to be able to infect MSCs *in vitro* and induces a cytopathic

effect, as evidenced by signs of swelling and detachment from walls (Sundin et al., 2006). Recently, Avanzi et al. (2013) demonstrated that fetal membrane (FM) derived-MSCs (FM-MSCs) are fully permissive to infection with herpes simplex virus 1 and 2 (HSV-1 and HSV-2), varicella zoster virus (VZV), and human cytomegalovirus (HCMV) but not with Epstein-Barr virus (EBV) and human herpes virus 6, 7, and 8 (HHV-6, 7, and 8). Although these viruses are capable of entering FM-MSCs, transient and limited viral gene expression occurs (Avanzi et al., 2013).

Conclusion

In conclusion, we have shown that HTLV-1 modifies important MSC characteristics, such as the formation of intracellular vesicle structures and the expression of the surface molecules ICAM-1, VCAM-1, and HLA-DR. However, the MSC ability to differentiate into adipocytes and osteocytes was not affected by HTLV-1. In addition, MSCs were found to be susceptible to HTLV-1 infection *in vitro*, and this finding was supported by the hypothesis that, as part of the regular immune surveillance process, HTLV-1-infected CD4⁺ and CD8⁺ T cells are able to traffic during primary infection and viral latency into the BM, where cell-to-cell contact over a prolonged period of time can lead to progressive HTLV-1 BM invasion and probable infection of BM resident cells (Grant et al., 2002). Understanding the biological mechanisms involved during HTLV-1 infection and knowing the target cells and the possible routes of HTLV-1 spread in the body may aid the development of an appropriate and effective management strategy for this infection that improves the quality of life of HTLV-1-infected individuals.

Methods

HTLV-1-seropositive individuals

HTLV-1-seropositive individuals were diagnosed from blood-donor candidates of the Regional Blood Center of Ribeirão Preto. Samples were also collected from HTLV-1-infected individuals belonging to the Neurology Department of the University Hospital, São Paulo, Brazil. The diagnosis of HTLV-1/2 infection was established by an antibody screening of serum/plasma samples using an enzyme immunoassay (EIA; ORTHO HTLV-1/2 Ab-capture ELISA test system, Ortho Clinical Diagnostics, Inc., Raritan, N, USA) followed by PCR confirmation using amplification primers for the *tax* and *LTR* regions of HTLV-1 and the *LTR* and *pX* regions of HTLV-2 according to previously described protocols (Pinto et al., 2012). The HTLV-1 group consisted of seven individuals classified as healthy asymptomatic HTLV-1 carriers (HAC; 57.1% females, 42.9% males; mean age = 46.2 years) and six individuals with HAM/TSP (83.3% females, 16.7% males; mean age = 51.5 years). The mean HTLV-1 proviral load was 2190.8 copies/10⁵ cells for HAC individuals and 7214.9 for HAM/TSP individuals. The healthy control group consisted of seven randomly selected blood donors from the same geographical region as the HTLV-1-positive individuals described above, and these had a mean age of 44.7 years (85.7% females, 14.3% males). This study was approved by the Institutional Ethics Committee at the General Hospital of the Faculty of Medicine in Ribeirão Preto, University of São Paulo, Brazil (Process number 12462/2010). All of the patients enrolled in this study signed a written informed consent form.

Isolation, culture, and characterization of the cells

Peripheral blood mononuclear cells (PBMCs). PBMCs were separated from the whole blood using Ficoll-Paque™ PLUS (GE Healthcare Biosciences, Upland, Sweden) according to the

manufacturer's instructions. The T cells phenotypic analysis for CD3⁺, CD8⁺, CD45⁺, and CD4⁺ was performed by flow cytometry (BD Multitest™, BD Biosciences, CA, USA). Immunomagnetic cell separation was performed to obtain CD4⁺ T cells (CD4 MicroBeads MACs Miltenyi Biotec, CA, USA).

MSC isolation. Approximately 10 mL of human bone marrow aspirates were collected from healthy donors. The mononuclear cells were separated by Ficoll-Paque™ PLUS (GE Healthcare Biosciences, Upland, Sweden), and the MSCs were isolated by plastic adherence and cultured at a concentration of 2–4 × 10⁵ cells/mL in 25-cm² flasks (Corning, NY, USA) with alpha minimum essential medium (α-MEM) (Gibco, NY, USA) supplemented with 15% heat-inactivated standard fetal bovine serum (HyClone, UT, USA), 2 mM L-glutamine (Gibco, Grand Island, NY, USA), and 1% penicillin–streptomycin (Gibco, NY, USA). The non-adherent T cells were removed after 72 h, and the formation of colonies was observed after 3 to 4 days. The plastic-adherent MSCs at passages 3–5 were used in the experiments. The cultured MSCs were immunophenotypically characterized using the following monoclonal antibodies: CD45-FITC (fluorescein isothiocyanate), CD31-FITC, HLA-DR-FITC, CD73-PE (phycoerythrin), CD146-FITC, CD90-PE, CD29-APC (allophycocyanin), CD44-FITC, CD13-PE, CD49e-PE, HLA-ABC-PE, CD34-APC, CD14-PE, CD54-PE, CD166-PE, and CD105-PerCP (peridinin chlorophyll protein complex) (BD Biosciences, CA, USA). The adipogenic, osteogenic, and chondrogenic MSC differentiation potential were evaluated as described below.

Cell lines. MT2 cells (HTLV-1-infected cell line) were cultured in RPMI (Gibco, NY, USA) supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin (Gibco, NY, USA). All of the cultures were maintained in a humidified atmosphere of 5% CO₂ at 37 °C.

Virus infection and co-culture assay

The HTLV-1 concentration was determined according to the following protocol. MT2 cells were cultured (1 × 10⁷) in complete RPMI medium for 24 h. The viral supernatant was collected, filtered through a 45-µm filter (Millipore, MA, USA), and ultracentrifuged at 10,000g for 2 h. The concentrated virus was quantified through p19 enzyme immunoassay (EIA) (ZeptoMetrix Corporation, NY, USA) according to the manufacturer's instructions and stored at –80 °C. The ability of HTLV-1 to infect MSCs was examined using concentrated virus and co-culture assays. Human MSCs (2.5 × 10³) at passages 3–5 were seeded into individual wells of a six-well culture plates for 24 h. Concentrated HTLV-1 (100 ng) was added to the MSC culture and maintained for 18 h. For the co-culture assay, MSCs were cultured in complete RPMI medium at 37 °C for 18 h with MT2 cells irradiated with 60,000 Gy at a ratio of 1:1 or with MT2 cells in a transwell system (Greiner Bio-one, NC, USA). As a control, we maintained cells in the same medium without addition of the virus. The experiments were repeated at least three times, and the results were calculated as the means ± SEM of triplicates.

Electron microscopy

MSCs co-cultured with MT2 cells for 18 h were fixed with 2.0% glutaraldehyde and 2% paraformaldehyde in 0.1 M (pH 7.2) cacodylate buffer supplemented with 5 mM MgCl₂, 5 mM CaCl₂, and 0.1 M sucrose. The filters were washed in cacodylate buffer and postfixed for 1 h at room temperature in 1% osmium tetroxide solution. The samples were washed three times in water and incubated in 0.5% uracil acetate. The cells were dehydrated in an ethanol gradient (from 25 to 100%) and embedded into epoxy resin at 60 °C for 48 h. After washing in propylene oxide, ultrathin

sections were cut using a Leica Ultracut S microtome. The sections were then examined using a JEOL JEM-100 CX II electron microscope.

Immunocytochemistry assay

Immunocytochemistry was performed to confirm the HTLV-1 infection of MSCs. MSCs co-cultured with MT2 cells (2 × 10⁴) or under control conditions were seeded on glass coverslips (Gold-Lab, SP, Brazil) in 24-well plates (Corning, NY, USA) and incubated until the cells reached 80% confluence. The cells were fixed in 4% paraformaldehyde (Merck, NJ, USA) for 20 min at room temperature, washed three times with PBS, and then permeabilized with 0.2% Triton X-100 (Sigma-Aldrich, MO, USA) for 1 h at room temperature. The cells were blocked for 1 h with 5% bovine serum albumin (BSA) and 2% goat serum diluted in PBS. The samples were separately incubated with primary anti-HTLV-1 p19 antibodies (Abcam, MA, USA) and CD73 (BD Pharmingen, CA, USA) at room temperature overnight. The secondary antibody used was Alexa Fluor 488 mouse antibody (Invitrogen, CA, USA). The nuclei were stained with DAPI (Vysis, IL, USA). The cells were visualized separately using a confocal laser scanning microscope (CLSM) (LSM 710; Carl Zeiss, Germany) with 20x and 63x objective lenses and a numerical aperture of 1.4. An argon 488-nm laser was used to excite the fluorochrome of the secondary antibodies, and the emission was measured at 525 nm. The visualization of the light scattering for each excitation wavelength was recorded in the multitracking mode using separate detection channels. The image analysis was performed using the ZEN2008 software (Carl Zeiss, Germany). The control and test images were captured using identical settings.

Flow cytometry analysis

The cultured MSCs were immunophenotypically characterized by flow cytometry using the following monoclonal antibodies: CD106 (VCAM1, vascular cell adhesion molecule 1)-PE, CD54 (ICAM-1, type I transmembrane protein)-PE, CD13-APC, HLA-DR (major histocompatibility complex, class II)-PE, CD271 (NGFR, nerve growth factor receptor)-PE, HLA-ABC-PE, CD73 (NT5E, 5-nucleotidase, ecto)-PE, CD105 (ENG, endoglin)-PerCP, and CD45 (Leukocyte common antigen)-FITC (BD Biosciences, CA, USA).

For the intracellular detection of *tax*, the cells were fixed in 1% paraformaldehyde (Sigma-Aldrich, MO, USA), permeabilized with 1% Tween 20, and stained with a specific antibody (kindly provided by Dr. Yuetsu Tanaka, University of the Ryukyus, Okinawa, Japan). For the analysis of the surface epitope by FACS, the cells were incubated with fluorescence-conjugated antibodies (1 µg per 10⁶ cells) at room temperature for 30 min. After washing twice with 1X PBS, the cells were suspended in PBS and analyzed using a FACScalibur flow cytometer (BD Biosciences, CA, USA). Ten thousand events were acquired and analyzed using the CellQuest software (BD Biosciences, CA, USA). Nonspecific IgG of the corresponding class served as a negative control.

MSC differentiation into adipocytes and osteocytes

The adipogenic and osteogenic differentiation of MSCs was obtained as described previously (Castilho-Fernandes et al., 2011). In brief, the differentiation was induced after incubation of the cells with specific differentiation media for adipocytes (α-MEM (Gibco-Invitrogen, CA, USA) supplemented with 15% FBS (Thermo Scientific HyClone, UT, USA), 1 mM dexamethasone (Dex; Sigma-Aldrich, MO, USA), 2.5 mg/mL insulin, and 0.5 mM isobutylmethyl-xanthine (Sigma-Aldrich, MO, USA)) and for osteocytes (α-MEM (Gibco-Invitrogen, CA, USA) supplemented with 7.5% FBS (Thermo

Scientific HyClone, UT, USA), 0.1 mM Dex (Sigma-Aldrich, MO, USA), 20 mM ascorbic acid, and 1 M β -glycerophosphate (Sigma-Aldrich, MO, USA)). The media were replaced every three days over a period of 22 days, and the cells were then fixed and stained through the von Kossa method (for calcium deposition) with Sudan II and Scarlet stains (for accumulation of fat). The control cells were maintained in standard α -MEM (Gibco, Invitrogen, CA, USA) with 7.5% fetal bovine serum (Thermo Scientific HyClone, UT, USA) over the same period. The cells were analyzed using an AxioScope 2.0 Zeiss microscope equipped with an AxioCam HR (Carl Zeiss, Jena, Germany) and by real-time PCR for the gene expression.

Quantitative real-time PCR (qRT-PCR)

The total cell RNA was extracted using an RNeasy mini kit (Qiagen, North Rhine-Westphalia, Germany) according to manufacturer's instructions and stored at -80°C . The quantity and quality of the RNA were assessed by spectrophotometry using a Nanodrop instrument (Thermo Fisher Scientific, NJ, USA). The complementary DNA (cDNA) was synthesized from 1 μg of total RNA using a high-capacity cDNA archive kit (Applied Biosystems, CA, USA). The cDNA was diluted 10 times in nuclease-free water and was used in each real-time PCR reaction. The SYBR[®] Green PCR mix (Applied Biosystems, CA, USA) was used to determine the gene expression of HTLV-1 receptors using the following primers: NRP1F, 5'-CCTGAATGTTCCAGAACTACACAA-3'; NRP1R, 5'-CAACATCAGGGAATCCATCCC-3'; HSPG2F, 5'-TGGACACATTCGTACCTTTCTGA-3'; HSPG2R, 5'-ACTCCGACTCCAGCGTGTCT-3'; GLUT1F, 5'-atggagcca cgacgaaga-3'; GLUT1R, 5'-agggaccagagcgtggtgag-3'. We also evaluated the gene expression of PPAR γ using the following primers: PPARF, 5'-TCCCGCTGACCAAAGCAAG-3'; PPARR, 5'-CAGGGGGGTGATGTG TTTGA-3'. The endogenous controls were human actin beta (ACTB; ACTBF, 5'-GCCCTGAGGCACTCTTCCA-3'; ACTBR, 5'-CCAGGGCAGTGATCTCCTTCT-3') and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; GAPDHF, 5'-GCCTCAAGATCATCAGCAATGC-3'; GAPDHR, 5'-CATGGACTGTGGTCATGACTCCT-3'). The single-product amplification was confirmed by the post-melting curve.

The quantitative RT-PCR was performed using TaqMan[™] assays for the *tax* and *env* HTLV-1 genes (specific probe FAM labeled), RUNX2 (Hs00231692_m1), CD106 (Hs00174239_m1), CD54 (Hs00164932_m1), and CD271 (Hs00609977_m1; Applied Biosystems, CA, USA). The reaction was performed in a final volume of 15 μL for 40 cycles under universal cycling conditions (40 cycles of 95 $^{\circ}\text{C}$ for 15 s and 60 $^{\circ}\text{C}$ for 1 min) in an ABI Prism 7500 sequence detection system (Applied Biosystems, CA, USA). The results were normalized using the geometric mean of the endogenous genes GAPDH, ACTB, and B₂ microglobulin (B2M). Duplicate samples were measured and averaged. The results are reported using expression relative units (Albesiano et al., 2003). The HTLV-1 proviral load was determined using the *pol* HTLV-1 and ACTB genes.

Statistical analysis

The assays were conducted in at least triplicate. To evaluate the differences between MSCs cultured under control conditions and MSCs exposed to HTLV-1, we used the Mann–Whitney *t* test. The results are expressed as the means \pm SEM. The statistical analysis was performed using GraphPad Prism (version 5.0; La Jolla, CA, USA), and differences were considered statistically significant if **p* < 0.05, ***p* < 0.01, and ****p* < 0.001.

Authors' contribution

Rodrigues E.S. was responsible for experimental design, cell cultures and statistics analyses, Macedo M.D. was responsible for cell cultures, Pinto M.T. was responsible for CD4⁺ T cells isolation and reverse transcription, Orellana M.D. was responsible for MSC isolations, Rocha-Junior M.C. conducted HTLV-1 particles concentration, Magalhães D.A.R. conducted immunocytochemistry assay, Takayanagui O.M. was responsible for HTLV-1 individuals assistance, Covas D.T. and Kashima S were responsible for the overall experimental design and coordination of the project.

Acknowledgments

This study was supported by CNPq Universal (Process number 477126/2009-0), Center for Cell-based Therapy (CTC), Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and Fundação Hemocentro de Ribeirão Preto (FUNDHERP). We are grateful to the staff and blood donors of Regional Blood Center of Ribeirão Preto and patients from the Neurology Department of the University Hospital. The authors thank Leonardo Lira do Amaral for the assistance in cell irradiation and Patrícia Vianna Bonini Palma for cytometry analyses. The authors acknowledge Svetoslav Nanev Slavov for scientific contribution and Fernanda Udinal for English language support. We also thank Sandra Navarro Bresciani for preparing the figures and Josiane Serrano Borges for technical support with glass coverslips.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at <http://dx.doi.org/10.1016/j.virol.2013.11.022>.

References

- Albesiano, E., Messmer, B.T., Damle, R.N., Allen, S.L., Rai, K.R., Chiorazzi, N., 2003. Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone. *Blood* 102, 3333–3339.
- Araújo, A.Q., Leite, A.C., Dultra, S.V., Andrada-Serpa, M.J., 1995. Progression of neurological disability in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). *J. Neurol. Sci.* 129, 147–151.
- Auletta, J.J., Deans, R.J., Bartholomew, A.M., 2012. Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. *Blood* 119, 1801–1809.
- Avanzi, S., Leoni, V., Rotola, A., Alviano, F., Solimando, L., Lanzoni, G., Bonsi, L., Di Luca, D., Marchionni, C., Alvisi, G., Ripalti, A., 2013. Susceptibility of human placenta derived mesenchymal stromal/stem cells to human herpesviruses infection. *PLoS One* 8 (8), e71412.
- Barnard, A.L., Igakura, T., Tanaka, Y., Taylor, G.P., Bangham, C.R., 2005. Engagement of specific T-cell surface molecules regulates cytoskeletal polarization in HTLV-1-infected lymphocytes. *Blood* 106 (3), 988–995.
- Bartholomew, A., Sturgeon, C., Siatskas, M., Ferrer, K., McIntosh, K., Patil, S., Hardy, W., Devine, S., Ucker, D., Deans, R., Moseley, A., Hoffman, R., 2002. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. *Exp. Hematol.* 30, 42–48.
- Castilho-Fernandes, A., de Almeida, D.C., Fontes, A.M., Melo, F.U., Picanço-Castro, V., Freitas, M.C., Orellana, M.D., Palma, P.V., Hackett, P.B., Friedman, S.L., Covas, D.T., 2011. Human hepatic stellate cell line (LX-2) exhibits characteristics of bone marrow-derived mesenchymal stem cells. *Exp. Mol. Pathol.* 91, 664–672.
- Cheng, K., Rai, P., Lan, X., Plagov, A., Malhotra, A., Gupta, S., Singhal, P.C., 2013. Bone-derived mesenchymal stromal cells from HIV transgenic mice exhibit altered proliferation, differentiation capacity and paracrine functions along with impaired therapeutic potential in kidney injury. *Exp. Cell Res.* 319 (14), 2266–2274.
- Choudhary, S., Marquez, M., Alencastro, F., Spors, F., Zhao, Y., Tiwari, V., 2011. Herpes simplex virus type-1 (HSV-1) entry into human mesenchymal stem cells is heavily dependent on heparan sulfate. *J. Biomed. Biotechnol.* 2011, 264350.
- Cotter, E.J., Malizia, A.P., Chew, N., Powderly, W.G., Doran, P.P., 2007. HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. *AIDS Res. Hum. Retroviruses* 23, 1521–1530.

- Cotter, E.J., Ip, H.S., Powderly, W.G., Doran, P.P., 2008. Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation. *BMC Musculoskelet. Disord.* 9, 33.
- Cotter, E.J., Chew, N., Powderly, W.G., Doran, P.P., 2011. HIV type 1 alters mesenchymal stem cell differentiation potential and cell phenotype ex vivo. *AIDS Res. Hum. Retroviruses* 27, 187–199.
- Di Nicola, M., Carlo-Stella, C., Magni, M., Milanese, M., Longoni, P.D., Matteucci, P., Grisanti, S., Gianni, A.M., 2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. *Blood* 99, 3838–3843.
- Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, A., Dj, Prockop, Horwitz, E., 2006. Minimal criteria for defining multipotent mesenchymal stromal cells: the International Society for Cellular Therapy position statement. *Cytotherapy* 8, 315–317.
- Donegan, E., Lee, H., Operskalski, E.A., Shaw, G.M., Kleinman, S.H., Busch, M.P., Stevens, C.E., Schiff, E.R., Nowicki, M.J., Hollingsworth, C.G., Mosley, J.W., 1994. Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1. *Transfusion* 34, 478–483.
- da Silva Meirelles, L., Chagastelles, P.C., Nardi, N.B., 2006. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. *J. Cell Sci.* 119, 2204–2213.
- Friedenstein, A.J., Gorskaja, J.F., Kulagina, N.N., 1976. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. *Exp. Hematol.* 4, 267–274.
- Gibellini, D., Alviano, F., Miserocchi, A., Tazzari, P.L., Ricci, F., Clò, A., Morini, S., Borderi, M., Viale, P., Pasquinelli, G., Pagliaro, P., Bagnara, G.P., Re, M.C., 2011. HIV-1 and recombinant gp120 affect the survival and differentiation of human vessel wall-derived mesenchymal stem cells. *Retrovirology* 8, 40.
- Grant, C., Barmak, K., Alefantis, T., Yao, J., Jacobson, S., Wigdahl, B., 2002. Human T cell leukemia virus type I and neurologic disease: events in bone marrow, peripheral blood, and central nervous system during normal immune surveillance and neuroinflammation. *J. Cell. Physiol.* 190, 133–159.
- Igakura, T., Stinchcombe, J.C., Goon, P.K., Taylor, G.P., Weber, J.N., Griffiths, G.M., Tanaka, Y., Osame, M., Bangham, C.R., 2003. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. *Science* 299, 1713–1716.
- Jacobson, S., McFarlin, D.E., Robinson, S., Voskuhl, R., Martin, R., Brehaw, A., Newell, A.J., Koenig, S., 1992. HTLV-I-specific cytotoxic T lymphocytes in the cerebrospinal fluid of patients with HTLV-I-associated neurological disease. *Ann. Neurol.* 32, 651–657.
- Jacobson, S., Krichavsky, M., Flerlage, N., Levin, M., 1997. Immunopathogenesis of HTLV-I associated neurologic disease: massive latent HTLV-I infection in bone marrow of HAM/TSP patients. *Leukemia* 11 (Suppl. 3), 73–75.
- Jones, K.S., Petrow-Sadowski, C., Huang, Y.K., Bertolette, D.C., Ruscetti, F.W., 2008. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. *Nat. Med.* 14, 429–436.
- Kiyokawa, T., Yamaguchi, K., Takeya, M., Takahashi, K., Watanabe, T., Matsumoto, T., Lee, S.Y., Takatsuki, K., 1987. Hypercalcemia and osteoclast proliferation in adult T-cell leukemia. *Cancer* 59, 1187–1191.
- LaGrenade, L., Hanchard, B., Fletcher, V., Cranston, B., Blattner, W., 1990. Infective dermatitis of Jamaican children: a marker for HTLV-I infection. *Lancet* 336, 1345–1347.
- Manns, A., Miley, W.J., Wilks, R.J., Morgan, O.S., Hanchard, B., Wharfe, G., Cranston, B., Maloney, E., Welles, S.L., Blattner, W.A., Waters, D., 1999. Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. *J. Infect. Dis.* 180, 1487–1493.
- Marandin, A., Canque, B., Coulombel, L., Gluckman, J.C., Vainchenker, W., Louache, F., 1995. In vitro infection of bone marrow-adherent cells by human immunodeficiency virus type 1 (HIV-1) does not alter their ability to support hematopoiesis. *Virology* 213, 245–248.
- Mariette, X., Agbalika, F., Zucker-Franklin, D., Clerc, D., Janin, A., Cherot, P., Brouet, J. C., 2000. Detection of the tax gene of HTLV-I in labial salivary glands from patients with Sjögren's syndrome and other diseases of the oral cavity. *Clin. Exp. Rheumatol.* 18, 341–347.
- Montanheiro, P.A., Montanheiro, P.A., Oliveira, A.C., et al., 2005. Human T-cell lymphotropic virus type I (HTLV-I) proviral DNA viral load among asymptomatic patients and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. *Braz. J. Med. Biol. Res.* 38, 1643–1647.
- Nagafuji, K., Harada, M., Teshima, T., et al., 1993. Hematopoietic progenitor cells from patients with adult T-cell leukemia-lymphoma are not infected with human T-cell leukemia virus type 1. *Blood* 82, 2823–2828.
- Nagai, M., Usuku, K., Matsumoto, W., Kodama, D., Takenouchi, N., Moritoyo, T., Hashiguchi, S., Ichinose, M., Bangham, C.R., Izumo, S., Osame, M., 1998. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. *J. Neurovirol.* 4 (6), 586–593.
- Oh, U., Jacobson, S., 2008. Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: toward rational targeted therapy. *Neurol. Clin.* 26, 781–797.
- Osame, M., Usuku, K., Izumo, S., Ijichi, N., Amitani, H., Igata, A., Matsumoto, M., Tara, M., 1986. HTLV-I associated myelopathy, a new clinical entity. *Lancet* 1, 1031–1032.
- Pinto, M.T., Rodrigues, E.S., Malta, T.M., Azevedo, R., Takayanagui, O.M., Valente, V.B., Ubiali, E.M., Covas, D.T., Kashima, S., 2012. HTLV-1/2 seroprevalence and coinfection rate in Brazilian first-time blood donors: an 11-year follow-up. *Rev. Inst. Med. Trop. Sao Paulo* 54, 123–129.
- Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A.I., Zhao, R.C., Shi, Y., 2008. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. *Cell Stem Cell* 2, 141–150.
- Ren, G., Zhao, X., Zhang, L., Zhang, J., L'Huillier, A., Ling, W., Roberts, A.I., Le, A.D., Shi, S., Shao, C., Shi, Y., 2010. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. *J. Immunol.* 184, 2321–2328.
- Romieu-Mourez, R., François, M., Boivin, M.N., Stagg, J., Galipeau, J., 2007. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. *J. Immunol.* 179, 1549–1558.
- Scadden, D.T., Zeira, M., Woon, A., Wang, Z., Schieve, L., Ikeuchi, K., Lim, B., Groopman, J.E., 1990. Human immunodeficiency virus infection of human bone marrow stromal fibroblasts. *Blood* 76, 317–322.
- Smirnov, S.V., Harbachevski, R., Lewis-Antes, A., Zhu, H., Rameshwar, P., Kotenko, S. V., 2007. Bone-marrow-derived mesenchymal stem cells as a target for cytomegalovirus infection: implications for hematopoiesis, self-renewal and differentiation potential. *Virology* 360, 6–16.
- Soderberg, C., Giugni, T.D., Zaia, J.A., Larsson, S., Wahlberg, J.M., Moller, E., 1993. CD13 (human aminopeptidase N) mediates human cytomegalovirus infection. *J. Virol.* 67, 6576–6585.
- Stagg, J., Pommey, S., Eliopoulos, N., Galipeau, J., 2006. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. *Blood* 107, 2570–2577.
- Starling, A.L., Martins-Filho, O.A., Lambertucci, J.R., Labanca, L., de Souza Pereira, S. R., Teixeira-Carvalho, A., Martins, M.L., Ribas, J.G., Carneiro-Proietti, A.B., Gonçalves, D.U., 2013. Proviral load and the balance of serum cytokines in HTLV-1-asymptomatic infection and in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). *Acta Trop.* 125 (1), 75–81.
- Sundin, M., Orvell, C., Rasmusson, I., Sundberg, B., Ringdén, O., Le Blanc, K., 2006. Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. *Bone Marrow Transplant* 37 (11), 1051–1059.
- Tang, S.W., Chen, C.Y., Klase, Z., Zane, L., Jeang, K.T., 2013. The cellular autophagy pathway modulates human T-cell leukemia virus type 1 replication. *J. Virol.* 87 (3), 1699–1707.
- Tendler, C.L., Greenberg, S.J., Burton, J.D., Danielpour, D., Kim, S.J., Blattner, W.A., Manns, A., Waldmann, T.A., 1991. Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: alternate molecular mechanisms underlying retroviral pathogenesis. *J. Cell. Biochem.* 46, 302–311.
- Uchiyama, T., 1997. Human T cell leukemia virus type I (HTLV-I) and human diseases. *Annu. Rev. Immunol.* 15, 15–37.
- Umehara, F., Izumo, S., Nakagawa, M., Ronquillo, A.T., Takahashi, K., Matsumuro, K., Sato, E., Osame, M., 1993. Immunocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV-I-associated myelopathy. *J. Neuropathol. Exp. Neurol.* 52, 424–430.
- Umehara, F., Izumo, S., Ronquillo, A.T., Matsumuro, K., Sato, E., Osame, M., 1994. Cytokine expression in the spinal cord lesions in HTLV-I-associated myelopathy. *J. Neuropathol. Exp. Neurol.* 53, 72–77.
- Wang, L., Mondal, D., La Russa, V.F., Agrawal, K.C., 2002. Suppression of clonogenic potential of human bone marrow mesenchymal stem cells by HIV type 1: putative role of HIV type 1 tat protein and inflammatory cytokines. *AIDS Res. Hum. Retroviruses* 18, 917–931.
- Waterman, R.S., Tomchuck, S.L., Henkle, S.L., Betancourt, A.M., 2010. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. *PLoS One* 5, e10088.
- Wei, G., Lin, M., Cai, Z., Huang, H., 2011. Cytomegalovirus infection in mesenchymal stem cells and their activation could be enhanced by nuclear factor- κ B inhibitor pyrrolidinedithiocarbamate in vitro. *Transplant Proc.* 43, 1944–1949.
- Yoshida, M., Seiki, M., Yamaguchi, K., Takatsuki, K., 1984. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. *Proc. Natl. Acad. Sci. USA* 81, 2534–2537.

Tax Posttranslational Modifications and Interaction with Calreticulin in MT-2 Cells and Human Peripheral Blood Mononuclear Cells of Human T Cell Lymphotropic Virus Type-I-Associated Myelopathy/Tropical Spastic Paraparesis Patients

Fernando Medina,^{1,*} Sebastian Quintremil,^{1,*} Carolina Alberti,¹ Andres Barriga,¹ Luis Cartier,² Javier Puente,¹ Eugenio Ramírez,³ Arturo Ferreira,⁴ Yuetsu Tanaka,⁵ and Maria Antonieta Valenzuela¹

Abstract

The human retrovirus human T cell lymphotropic virus type-I (HTLV-1) is the etiologic agent of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Axonal degeneration in HAM/TSP patients occurs without neuron infection, with the secreted viral Tax protein proposed to be involved. We previously found that Tax secreted into the culture medium of MT-2 cells (HTLV-1-infected cell line) produced neurite retraction in neuroblastoma cells differentiated to neuronal type. To assess the relevance of Tax posttranslational modifications on this effect, we addressed the question of whether Tax secreted by MT-2 cells and peripheral blood mononuclear cells (PBMCs) of HTLV-1-infected subjects is modified. The interaction of Tax with calreticulin (CRT) that modulates intracellular Tax localization and secretion has been described. We studied Tax localization and modifications in MT-2 cells and its interaction with CRT. Intracellular Tax in MT-2 cells was assessed by flow cytometry, corresponding mainly to a 71-kDa protein followed by western blot. This protein reported as a chimera with gp21 viral protein—confirmed by mass spectrometry—showed no ubiquitination or SUMOylation. The Tax–CRT interaction was determined by confocal microscopy and coimmunoprecipitation. Extracellular Tax from HAM/TSP PBMCs is ubiquitinated according to western blot, and its interaction with CRT was shown by coimmunoprecipitation. A positive correlation between Tax and CRT secretion was observed in HAM/TSP PBMCs and asymptomatic carriers. For both proteins inhibitors and activators of secretion showed secretion through the endoplasmic reticulum–Golgi complex. Tax, present in PBMC culture medium, produced neurite retraction in differentiated neuroblastoma cells. These results suggest that Tax, whether ubiquitinated or not, is active for neurite retraction.

Introduction

HUMAN T CELL LYMPHOTROPIC VIRUS TYPE-I (HTLV-1), the first human retrovirus discovered in the early 1980s, is the etiologic agent of two human pathologies: adult T cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).^{1,2} HAM/TSP is a progressive neurological disease characterized by a central

axonopathy, probably due to an axoplasmic transport disorder that produces a selective loss of long axons of corticospinal tracts.^{3,4} Regarding infection, T-CD4⁺ cells are the *in vivo* reservoir of the virus, mainly CD4⁺FoxP3⁺ cells or T_{reg}.^{5–7} Human cerebral endothelial cells have been shown to be susceptible to retroviral infection, producing a dysfunction of the blood–brain barrier by alteration in the expression of tight-junction proteins.⁸ This could be an important

¹Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.

²Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

³Programa de Virología, Facultad de Medicina, Universidad de Chile, and Departamento de Virología, ISP, Santiago, Chile.

⁴Programa de Inmunología, ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

⁵Department of Immunology, Graduate School and Faculty of Medicine, University of the Ryukyus, Nishihara, Japan.

*These authors contributed equally to this work.

mechanism for the infiltration of infected lymphocytes into the central nervous system (CNS) and also facilitates astrocyte infection.

Despite increasing knowledge about HTLV-1, the molecular mechanisms in HAM/TSP and the progression of the disease are still unknown since HTLV-1 does not infect *in vivo* neurons.⁹ HAM/TSP has been associated with the expression and secretion of HTLV-1 Tax pleiotropic protein that exerts a role in viral and cellular transcription, cellular proliferation, and transformation.^{4,10–16} Among the viral proteins, Tax is chronically detected in the cerebrospinal fluid of HAM/TSP patients.¹⁷ Incubation of human SH-SY5Y neuroblastoma cells with culture medium of MT-2 cells (an HTLV-1-infected cell line that secretes viral Tax protein) produces neurite retraction and an increase in Tau phosphorylation at T181.¹⁸

Tax, a 40-kDa protein, undergoes posttranslational modifications such as phosphorylation, ubiquitination, SUMOylation, and acetylation.^{15,16,19–24} Phosphorylation is critical for Tax transactivation via both the ATF/CREB and NF- κ B pathways.^{19,25} Ubiquitinated Tax is associated with cytoplasmic location, while SUMOylation is a nuclear retention signal of Tax resulting in NF- κ B transcriptional activation.^{20–24} Acetylation, predominantly in the nucleus, also facilitates NF- κ B activation and positively correlates with Tax phosphorylation, being improved by previous SUMOylation.^{15,25}

Recently, a critical role of K63-linked polyubiquitination of Tax has been shown at lysines K4 to K8 for Tax-induced NF- κ B activation.^{26,27} This modification is essential for Tax binding to NEMO/IKK- γ and IKK activation, while SUMOylation is dispensable. Tax nuclear import/export would occur through carrier- and energy-independent transport mechanisms; Tax may also have a carrier function.^{12,28,29} Nevertheless, no Tax posttranslational modification studies have been performed in constitutively HTLV-1-infected lymphocytes (MT-2 cells) and in secreted products from HTLV-1 lymphocytes of infected individuals.

Alefantis *et al.*³⁰ reported that the calcium-binding protein calreticulin (CRT) interacts with Tax-GFP in BHK transfected cells, and the fluorescence signal was located near or at the nuclear membrane. They also observed in infected cells, including MT-2 cells, a higher expression of CRT compared with noninfected cell lines. Expression of Tax in Hep2 cells leads to a redistribution of CRT from the nucleus to the cytoplasm as shown by confocal microscopy with colocalization of Tax, CRT, NEMO/IKK- γ , and RelA in cytoplasmic dotted structures.³¹

Tax contains a number of putative secretory signals including YTN1 and DHE, and interacts with cellular secretory pathway proteins in both a transfected cell line (BHK-21) and in an HTLV-1-infected cell line (C8166 cells, a human CD4⁺ T lymphoblastoid cell line).¹³ The secretion of Tax would occur by classical secretory pathways involving a vesicular transport mechanism through the endoplasmic reticulum (ER) and Golgi complex.^{11,13,28}

The detection of Tax in cerebrospinal fluid of HAM/TSP patients and the neurite retraction produced by secreted products from MT-2 cells suggest that Tax could be a relevant protein in the pathogeny. In the present study, we followed Tax modifications with ubiquitin, SUMO-1, and SUMO-2/3 in MT-2 cells and in peripheral blood mono-

nuclear cell (PBMC) culture medium from HTLV-1-infected subjects. In addition, CRT was determined in both types of samples to study Tax–CRT interaction/relationships and Tax posttranslational modifications related to HAM/TSP pathogenesis. Finally, we investigated whether Tax secreted from PBMCs of HAM/TSP patients also produced neurite retraction in neuroblastoma cells differentiated to neuronal type as Tax present in MT-2 cell culture medium.

Materials and Methods

Cell culture

Five to ten million MT-2 or K562 cells (control cell line) were cultured in 10 ml of RPMI 1640 + GlutaMAX (Invitrogen, Eugene, OR) supplemented with 10% fetal bovine serum (Invitrogen) as reported by Ramírez *et al.*³²

HAM/TSP patients, asymptomatic HTLV-1 carriers, and healthy noninfected control subjects

All the experiments were performed in compliance with relevant laws and institutional guidelines and in accordance with the ethical standards of the Declaration of Helsinki. The University of Chile Ethics Committee has approved the research protocol and all individuals freely gave informed written consent. EDTA-treated blood was obtained from 14 HAM/TSP patients, three asymptomatic HTLV-1 carriers, and six healthy noninfected subjects (negative control).

PBMCs isolation and culture

PBMCs were isolated from 10 ml of EDTA-treated blood samples by Ficoll-Hypaque density gradient centrifugation and then were washed three times with phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 100 mM Na₂HPO₄, 2 mM KH₂PO₄, pH 7.2). We collected 2 × 10⁶ PBMCs from each sample, which were cultured for 24 h in 1 ml of RPMI 1640 + GlutaMAX medium supplemented with 10% fetal bovine serum. The action of CD8⁺ cytotoxic T lymphocytes was inhibited by 20 nM concanamycin A (Sigma-Aldrich, St Louis, MO) in order to express measurable Tax.³³ In Tax and CRT kinetics experiments from PBMCs, 1 μ g/ml Brefeldin A (BFA) or 1 μ g/ml ionomycin (IM) and 30 ng/ml phorbol myristate acetate (PMA) were added to the culture at 6 h. The cytotoxicity of BFA and IM + PMA treatments was assayed by measuring LDH release using the Pierce LDH Cytotoxicity Assay Kit, according to the manufacturer's instructions.

Flow cytometry

Cultured MT-2 cells (300,000) were harvested and washed twice with PBS and centrifuged at 400 × *g* for 2 min. They were then stained with fluorophore-conjugated antibodies against CD4-FITC (dilution 1:25) (BD Biosciences, San Jose, CA) and Tax-APC (dilution 1:100) prepared in Dr. Yuetsu Tanaka's Laboratory. For Tax staining, cells were treated with 100 μ l of fixation/permeabilization solution (eBiosciences, San Diego, CA) for 15 min at 4°C. Matched isotype controls were used at the same concentration as the respective antibodies. We performed two-color flow cytometry in a FACS-CANTO instrument (Beckton Dickinson); WinMDI 2.9 software was used for data analysis.

Immunocytochemistry and confocal microscopy

MT-2 and K562 cells were washed four times at 37°C with PBS. Cells were deposited on glass slides at a density of 10^4 cells per $10\ \mu\text{l}$, allowed to dry for 2–3 h at room temperature, fixed, and permeabilized in ice-cold acetone for 8 min. Fixed cells were incubated for 40 min at 37°C with $25\ \mu\text{l}$ of both monoclonal anti-Tax (Covalab, diluted 1:50) and polyclonal anti-CRT (prepared in Dr. Arturo Ferreira's laboratory, diluted 1:200). After three washings with $250\ \mu\text{l}$ PBS, cells were incubated in darkness for 40 min at 37°C with $25\ \mu\text{l}$ of antimouse IgG secondary antibodies conjugated with FITC (Invitrogen, diluted 1:200) and antirabbit IgG conjugated with Alexa Fluor 594 (Invitrogen, diluted 1:400). The nuclear marker TO-PRO (Invitrogen) diluted 1:400 was also included. Cells were then washed three times with $250\ \mu\text{l}$ of PBS and once with MilliQ water and led dried at room temperature. Coverslips were added with $2\ \mu\text{l}$ of Gel mount Aqueous mounting medium (Sigma-Aldrich Inc.). The preparations were examined under a Carl Zeiss LSM 510 Meta confocal microscope. The images were obtained with LSM 510 Image Browser, and colocalization was analyzed with ImageJ, plugin Colocalization Finder software.

Cell lysis

Cells (MT-2, K562, or PBMCs) were washed five times with PBS and the last pellet was resuspended in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.5% Nonidet P-40, 10 mM *N*-ethylmaleimide, 0.2 mM Na_3VO_4 , and 0.1 mM PMSF, pH 7.5). A total of 2×10^6 cells per $500\ \mu\text{l}$ of lysis buffer was incubated on ice for 30 min with gentle shaking. Cell debris was pelleted by centrifugation at $16,000 \times g$ for 5 min at 4°C. The lysate was kept at -20°C . Subcellular fractionation of MT-2 cells was performed according to Kfoury *et al.*²³ to obtain three different fractions enriched in cytoplasmic, intermediate fraction (organellar membrane), and nuclear components.

Protein determination, SDS-PAGE, and western blot analysis

Protein determination of cell lysate was done using the Micro BCA Protein Assay Kit from Pierce (Pierce Biotechnology Inc., Rockford, IL) according to the manufacturer's instructions. SDS-PAGE under reducing conditions was performed with 10% polyacrylamide gels. Portions of $50\ \mu\text{g}$ protein of cell lysate or $20\ \mu\text{l}$ of PBMC culture medium were used. The buffer for electrotransfer to nitrocellulose membranes (Bio-Rad Laboratories Ltd., Hercules, CA) contained 25 mM Tris-HCl, 192 mM glycine, and 20% methanol, and electrotransfer was done at a total current of 600 mA at 4°C. After electrotransfer, membranes were blocked for 20 min at room temperature with 5% p/v of "Quick blocker" (Chemicon International, Temecula, CA) dissolved in TBS-T (20 mM Tris-HCl, 137 mM NaCl, 0.1% Tween-20, pH 7.6), then incubated overnight at 4°C or 2 h at room temperature with different primary antibodies at the appropriate dilution in TBS-T buffer.

The following monoclonal antibodies were used: two anti-Tax antibodies (Covalab, Cat. mab0022, diluted 1:1,000) and HTLV-1 Tax hybridoma 168A51-2 (NIH, AIDS Reagent Program, Germantown, MD; Cat. 1316, used as ascitic fluid,

diluted 1:1,000), antibodies against ubiquitin (Upstate, Lake Placid, NY; Cat. 04-263, diluted 1:1,000), SUMO-1 (Upstate; Cat. 04-453, diluted 1:1,000), SUMO-2/3 (Abcam Inc., Cambridge, MA; Cat. Ab3742, diluted 1:1,000), GAPDH (Sigma-Aldrich Inc.; Cat. G8795, diluted 1:20,000), TFIIB (Santa Cruz Biotechnology Inc., Santa Cruz, CA; Cat. sc-225, diluted 1:1,000), Dynein IC1/2, cytosolic (Santa Cruz Biotechnology Inc.; Cat. sc-13524, diluted 1:500), MMP-9 (Millipore Merck, Billerica, MA; Cat. MAB3309, diluted 1:500), and polyclonal antibodies against CRT prepared in Dr. Arturo Ferreira's laboratory (diluted 1:5,000 or 1:800,000 according to the antibody titer). After washing five times (5 min each wash) with TBS-T, membranes were incubated with the appropriate secondary antibody for 1 h at room temperature.

As secondary antibodies the following were used: ImmunoPure Goat Anti-Rabbit IgG (H+L) Peroxidase Conjugated (Pierce, diluted 1:500,000), ImmunoPure Goat Anti-Mouse IgG (H+L) Peroxidase Conjugated (Pierce, diluted 1:500,000), and Donkey Anti-Mouse antibody, HRP conjugated, diluted 1:250 (SA1100, Thermo Fisher Scientific, Rockford, IL; absorbed against the sera of several animal species). After washing five times (5 min each wash) with TBS-T the reaction product was visualized using enhanced chemiluminescence SuperSignal West Femto Maximum Sensitivity Substrate Chemiluminescent substrate (Pierce). X-Ray films (CL-Xposure film, Pierce) were exposed for varying times. Control experiments without primary antibodies (only with secondary antibodies) did not give any chemiluminescent signal. For consecutive analyses with various antibodies, stripping was performed, rinsing twice for 10 min with 200 mM glycine, 3.5 mM SDS, and 10% Tween-20 at pH 2.2. Blots were then blocked and probed as described above. Quantification of blots was carried out by scanning films using the Uni-Scan-It Automated Digitizing System.

Coimmunoprecipitation studies

Portions of $500\ \mu\text{g}$ of protein from cell lysates or $500\ \mu\text{l}$ of PBMC culture medium were captured with either anti-Tax (Covalab), anti-CRT, anti-Dynein, or anti-MMP-9 antibodies bound to the coupling resin of the "AminoLink Plus Immobilization Kit" (Pierce). Tax and CRT antibody binding, sample application, and protein elution were done according to the manufacturer's instructions. Proteins eluted from the matrix were subjected to SDS-PAGE and/or western blot.

Mass spectrometry analysis

Excised protein bands (stained with GelCode Blue Stain Reagent, Bio-Rad) were destained, DTT and iodoacetamide treated, and proteolyzed with Trypsin. Peptides from proteolysis and extraction were concentrated using SpeedVac. Concentrated peptides were redissolved in $10\ \mu\text{l}$ of 0.1% formic acid for MALDI-TOF analysis or in $30\ \mu\text{l}$ of 0.1% formic acid and 5% methanol for LC-MS/MS analysis. For MALDI-TOF analysis, the dissolved peptides were mixed with CHCA matrix (10 mg/ml) in a 1:1 ratio. Spectra were acquired in a Microflex MALDI-TOF instrument (Bruker Daltonics Inc., Billerica, MA). Mass list was analyzed in Mascot, MS-Fit, and ProFound on-line databases. Additionally, experimental data were examined using the PeptideMap tool from PROWL against the Tax sequence. For LC-MS/MS analysis $20\ \mu\text{l}$ of the dissolved peptides was

separated on a C_{18} column (Jupiter-Proteo 150 \times 1.0 mm, 4 μ m, and 90 \AA , Phenomenex Inc., Torrance, CA) at room temperature using the following conditions: 0–10 min 2% B, 10–70 min 2–100% B, and 70–80 min 100% B, where mobile phase A was 0.1% formic acid in water and mobile phase B was 0.085% formic acid in 80% acetonitrile. Chromatograms and spectra were recorded at positive mode on an Esquire 4000 LC-ESI IT MS/MS instrument (Bruker Daltonik GmbH, Germany). Experimental data were examined on the Mascot on-line database and on the local Mascot server against Tax (GenBank accession number BAB18052) and Env protein (GenBank accession number AAU04944) sequences.

Neurite retraction studies on SH-SY5Y cells

Neuroblastoma cells were differentiated with 10 μ M *all-trans*-retinoic acid (Sigma-Aldrich) and 50 ng/ml of BDNF (Alomone Laboratories, Jerusalem, Israel).¹⁸ BDNF was removed from the culture medium and replaced by a mixture of DMEM-F12 Ham without fetal bovine serum 4 h previous to the addition of culture medium of PBMCs. In all experiments DMEM-F12 was replaced by PBMC culture medium, being differentiated in SH-SY5Y cells incubated up to 2 h with (1) culture medium of PBMCs from an HAM/TSP patient, (2) culture medium of PBMCs from an HAM/TSP patient with 10 μ l/ml of either Tax antibody (HTLV-1 Tax Hyb 168A51-2) or a same isotype irrelevant antibody (anti-Gizzerosine), and (3) with culture medium of PBMCs from a healthy subject. Neurite retraction was followed measuring neurite length using the NIH ImageJ-1.38d program plug in NeuronJ according to Maldonado *et al.*¹⁸ Data collected from 200–300 neurites were used for each condition. All experiments were done in triplicate. Neurite length was expressed as the average value of (μ m)/cell \pm SEM.

Statistical analysis

Statistical data analysis was performed using GraphPad Prism 5.0 and SPSS (version 13, SPSS Inc., Chicago, IL). Data were verified for Gaussian distribution using the Shapiro Wilk test. Spearman's correlation coefficient was used to evaluate relationships between Tax and CRT protein levels.

Results

Tax expression, localization, and modifications in MT-2 cells

MT-2 cells are widely used as a lymphoid line in HTLV-1 research because they contain HTLV-1 in their genome as a provirus. About 50% of these cells express Tax followed by flow cytometry as is shown in Fig. 1A. Cell fractionation yielded fractions enriched in (1) cytosolic proteins, (2) cell membrane and organelle proteins (intermediate fraction), and (3) nuclear proteins.²³ Tax in western blot analysis corresponds mainly to a 71-kDa protein as shown in Fig. 1B. This band is observed only in the intermediate fraction. To evaluate the presence of modifications, antibodies against ubiquitin, SUMO-1, and SUMO-2/3 were used in western blot analysis. However, neither of them was found to be associated with the 71-kDa band (data not shown). Additionally, Tax immunoprecipitation did not enable detection of these posttranslational modifications.

According to the literature, Tax could be fused with Env or Gag proteins in MT-2 cells as a consequence of chromosomal aberration.^{34,35} Glycosylated Env is an immature protein that undergoes a proteolytic processing giving rise to two glycosylated membrane proteins, gp46 and gp21. Therefore, the C-terminal end of gp21 could be fused with translated Tax (Env-Tax). Tax was submitted to immunoprecipitation, Trypsin digestion, and MALDI-TOF/ESI-IT mass spectrometry analysis. The sequences of two Tax peptides (41-HALLATCPEHQITWDPIDGR-60 and 87-VLTPPITHTTPNIPPSFLQAMR-108) and two gp21 peptides (441-EALQ TGITLVALLLL VILAGPCILR-465 and 469-HLPSRVRY PHYSYLINPESSL-488) were found. These results are in agreement with the previously described fusion protein between gp21 and Tax present in MT-2 cells, accounting for the difference in electrophoretic migration, discarding ubiquitin-like posttranslational modifications.

Tax, upon 2-fold concentration from MT-2 culture medium, was found only as a 40-kDa nonmodified form by western blot (unpublished results). The 71-kDa membrane-associated form was not found as expected, because it is not a secretable protein.




FIG. 1. Tax expression in MT-2 cells. (A) Flow cytometry analysis of MT-2 cell culture, showing about 50% of Tax expressing cells (anti-Tax APC diluted 1:100). (B) Western blot of MT-2 or K562 cell fractionation into cytosolic (lanes 1), intermediate (lanes 2), and nuclear (lanes 3) fractions. The figure shows western blots using antibodies against Tax (Covablab, diluted 1:1,000), GAPDH (cytosolic marker, diluted 1:20,000), calreticulin (CRT) ER marker, diluted 1:5,000), and TFIIIB (nuclear marker, diluted 1:1,000).

Tax and CRT interaction in MT-2 cells

According to the literature, Tax is a secretable protein in *tax*-transfected cells and CRT seems to be involved in the Tax nuclear export into the cytoplasm.^{12,30} Consequently, CRT could participate in Tax intracellular localization, including secretion mechanisms. The interaction between Tax and CRT was determined by immunofluorescence colocalization and coimmunoprecipitation in MT-2 cells. According to confocal microscopy among a total of 500 observed cells, 57% expressed Tax protein, which agrees with previous flow cytometry data analysis (Fig. 1A). A total of 42% of Tax expressing cells showed CRT colocalization (Fig. 2A). The interaction between these proteins was confirmed by coimmunoprecipitation with either anti-Tax or anti-CRT antibodies (Fig. 2B). None of the immunoprecipitated complexes showed the presence of other irrelevant proteins (SUMO-1, SUMO-2/3, and ubiquitin). Immunoprecipitation using an irrelevant antibody (Dynein) as a negative control demonstrated the absence of Env-Tax and CRT (Fig. 2B), pointing to a specific interaction of Tax and CRT that could be involved in the secretion pattern of Tax in HTLV-1-infected cells.

Tax expression in cultured PBMCs from infected subjects

After 24 h culture, PBMCs from HTLV-1-infected patients expressed Tax protein at detectable levels by flow cytometry,⁷ but not by western blot. Nevertheless, secreted Tax can

be followed by western blot in PBMC culture medium, which indicates Tax secretion. We did not find a significant correlation between Tax content in HAM/TSP patients and disease progression. Posttranslational modifications determined in secreted Tax from infected PBMCs by western blot of the culture medium from a set of different HAM/TSP patients and asymptomatic HTLV-1 carriers showed an immunoreactive band for Tax that matches that for ubiquitin (Fig. 3A). Tax ubiquitination was confirmed after immunoprecipitation with anti-Tax antibodies, while modifications with SUMO-1 or SUMO-2/3 were not detected in that immunoprecipitate, which agrees with a secreted protein form (Fig. 3B). Since ubiquitin's molecular weight is about 8.5 kDa, the 57-kDa form might correspond to Tax modification with two ubiquitin subunits. Differences observed in Tax electrophoretic migration in Fig. 3B are caused by serum proteins in PBMC culture medium that are absent in the immunoprecipitated sample.

Tax and CRT secretion in PBMCs of HAM/TSP patients

CRT was found in the PBMC culture medium of HAM/TSP patients as a broad band (ranging from 87 to 70 kDa) and a discrete band at 56 kDa (Fig. 4A). To understand the secretion mechanisms of CRT and Tax protein, PBMCs of three patients were incubated with either Brefeldin A or with ionomycin (IM) and phorbol myristate acetate (PMA). The former inhibits protein transport from the ER to the Golgi; the




FIG. 2. Tax and CRT interaction in MT-2 cells. (A) Indirect immunofluorescence of Tax (anti-Tax Covalab diluted 1:50; secondary antibody FITC labeled, green) and CRT (anti-CRT diluted 1:200; secondary antibody Alexa Fluor 594 labeled, red)-stained MT-2 and K562 cells by confocal microscopy. Nuclei were labeled with TO-PRO (blue pseudocolor). White arrows indicate colocalization points of Tax and CRT. (B) Coimmunoprecipitation of Env-Tax and CRT from whole cells lysate of MT-2 cells. Tax and CRT were detected by western blot (WB) in both, Tax and CRT immunoprecipitated (IP), using anti-Tax NIH diluted 1:1,000 and anti-CRT diluted 1:5,000. As control, immunoprecipitation with anti-Dynein was performed. Dynein was detected by western blot using anti-Dynein diluted 1:500.




FIG. 3. Tax posttranslational modifications in peripheral blood mononuclear cell (PBMC) culture medium from HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. (A) Representative western blot for Tax identification (using antibodies against Tax, Covalab diluted 1:1,000) and ubiquitin modification in PBMC culture medium of HAM/TSP patients (lanes 1, 2, 4, 5, and 8), asymptomatic carriers (lanes 3 and 6), and healthy noninfected control (lane 7) determined by western blot. (B) Tax immunoprecipitation (IP) from PBMC culture medium (CM) and identification of Tax (using antibodies against Tax, NIH diluted 1:1,000), ubiquitin (diluted 1:1,000), SUMO-1 (diluted 1:1,000), and SUMO-2/3 (diluted 1:1,000) by western blot.

latter—IM and PMA—increase protein secretion. Cytotoxicity assays measured as LDH release, expressed as mean value \pm SD, showed the following values: for BFA treatment 0.210 ± 0.012 , for IM+PMA treatment 0.176 ± 0.085 , and for the control condition 0.237 ± 0.023 after 12 h culture. No sig-

nificant differences among the three conditions were found. The results obtained agree with a canonical secretion mechanism for both proteins in HTLV-1-infected PBMCs: Brefeldin A reduced the secretion of both Tax and CRT proteins, while IM and PMA increased their secretion levels (Fig. 4B).




FIG. 4. Tax and CRT secretion from PBMCs of HAM/TSP patients. (A) Representative western blot for CRT secreted from PBMC samples of HAM/TSP patients (lanes 1, 2, 4, 5, and 8), asymptomatic carriers (lanes 3 and 6), and healthy noninfected control (lane 7) determined in PBMC culture medium by western blot (anti-CRT, diluted 1:5,000). (B) Tax and CRT kinetics release from PBMCs of a representative HAM/TSP patient. Cells were cultured in control condition (Control) and determinations were made after 16 h of PBMC culture in the presence of Brefeldin A (BFA) or ionomycin/PMA (IM/PMA). Proteins were determined by western blot during 24 h of culture (anti-Tax NIH diluted 1:1,000 using as secondary antibody a donkey antimouse 1:250 absorbed against the sera of several animal species; anti-CRT diluted 1:800,000). Data are expressed in arbitrary units (AU) of pixel intensity corresponding to Tax and CRT normalized with respect to the initial value. (C) Direct relationship between Tax and 56-kDa CRT (AU) released levels from PBMC culture medium of HAM/TSP patients shown in (B). A significant positive correlation of 0.766 was found according to Spearman's correlation ($p < 0.05$, 24 data of XY pairs). (D) Coimmunoprecipitation of Tax and CRT from PBMC culture medium. Tax and CRT were detected by western blot (WB) in both Tax and CRT immunoprecipitations (IP). As control, immunoprecipitation with anti-MMP-9 was performed. MMP-9 was detected by western blot using anti-MMP-9 diluted 1:500.




FIG. 5. Effect of PBMC culture medium on SH-SY5Y neurite length. Neurite length, expressed as ($\mu\text{m}/\text{cell} \pm \text{SEM}$) collected from 200–300 neurites for each condition, was measured using the NIH ImageJ-1.38d program plug in neuronJ. Differentiated SH-SY5Y cells were incubated with PBMC culture medium of a noninfected subject (healthy subject), of an HAM/TSP patient, and the same culture of the HAM/TSP patient including anti-Tax (HTLV-1 Tax Hyb 168A51-2). After 30 min of treatment, significant differences between the HAM/TSP sample and the two control conditions were found ($p < 0.05$).

A positive correlation (Spearman's correlation coefficient of 0.8) between Tax protein and the 56-kDa band of CRT was found in PBMC culture medium of 14 HAM/TSP patients and three HTLV-1 carriers studied (data not shown). A similar positive correlation was determined between Tax and CRT during the time course of secretion of PBMCs cultured with Brefeldin A or IM/PMA for the three patients under study (Fig. 4C). Immunoprecipitation with either anti-Tax or anti-CRT antibodies from PBMC culture medium indicated coprecipitation of Tax and CRT (Fig. 4D). Immunoprecipitated complexes did not show other irrelevant proteins such as SUMO-1 and SUMO-2/3. Immunoprecipitation with an irrelevant antibody (MMP-9, secretable protein), used as negative control, evidenced the absence of Tax and CRT (Fig. 4D), confirming the specific interaction between these proteins. All these results suggest a common vesicular transport for secretion of both proteins.

Effect of secreted Tax from human PBMCs on neurite retraction of SH-SY5Y cells

Figure 5 shows the effect of PBMC culture medium of an HAM/TSP patient on differentiated neuroblastoma cells, SH-SY5Y cells, using as control the culture medium of a healthy subject. Neurite retraction (neurite shortening) was observed with secreted medium from PBMCs of the HAM/TSP patient. Inclusion of anti-Tax antibody prevented the retraction effect. The presence of an irrelevant antibody did not modify the neurite shortening produced by PBMC culture medium of the HAM/TSP patient (data not shown).

Discussion

Tax regulation and interaction with cellular proteins and transcriptional complexes in HTLV-1-infected cells are widely accepted as essential factors in virus replication and disease progression.¹⁴ Posttranslational modifications of Tax modulate its transcriptional activities and intracellular

localization.³⁶ Tax protein has been detected in the nucleus and in three extranuclear compartments: around the microtubule organizer center, colocalizing with the centrosome and associated with the Golgi complex, and also in the region of the virological synapse.^{23,37} Tax localization in both the nucleus and cytoplasm is important for activation of the NF- κ B pathway.²⁴ The canonical NF- κ B pathway requires NEMO/IKK- γ , which acts as a platform for recruitment of activators and inhibitors of the IKK complex (effector subunits IKK- α and IKK- β).²⁴ K63-linked polyubiquitination at lysines K4 to K8 of Tax promotes the targeting of Tax and NEMO to perinuclear spots associated with the Golgi complex. After their interaction with IKK- α and IKK- β , nuclear translocation of RelA occurs.^{24,26,27}

In HAM/TSP patients, the mechanisms related to extracellular Tax on disease occurrence and progression remain to be elucidated. In this pathology, the extracellular Tax action has been considered relevant mostly because of the following evidence: (1) about 40% of patients with paraparesis are seronegative for HTLV-1 but exhibit a truncated virus form with the Tax gene incorporated¹⁰ and (2) the neurite shortening (retraction) effect of secreted Tax from culture medium of MT-2 cells on differentiated human neuroblastoma cells.¹⁸ In this *in vitro* model of the disease, we also found an increase in Cdk5 activity that could be involved in extracellular Tax signaling. The participation of this viral protein was confirmed by the blocking effect of anti-Tax antibodies.¹⁸

Cell-free Tax detected in cerebrospinal fluid of HAM/TSP patients comes from secretion of infected cells, mainly CD4⁺ T cells.¹⁷ Increasing evidence suggests an extracellular axonal effect of Tax protein related to the occurrence and progression of HAM/TSP.^{13,18,30,38} Infected lymphocytes are initially in the CNS regions including periventricular areas of the blood–brain barrier, the subarachnoid space, and the thoracic and lumbar region.³⁹ Brain endothelial cells that express the receptors for HTLV-1 (GLUT-1, Neuropilin-1, and HSPG) can be infected, producing a dysfunction of the brain–blood barrier, increasing its permeability, thus facilitating lymphocyte passage through the endothelial monolayer cells.⁸

We identified ubiquitinated Tax protein in the culture medium of PBMCs isolated from HTLV-1 carriers and HAM/TSP patients (Fig. 3). Isolated Tax showed the presence of at least two ubiquitin units deduced from a molecular weight of 57 kDa. This modification should correspond to K63-linked ubiquitination since K48-linked ubiquitination is related to proteasomal degradation.⁴⁰ The lack of SUMO groups corroborated that Tax corresponds to a secreted protein form since this modification is considered a nuclear retention signal.^{21,22} To our knowledge, this is the first evidence of ubiquitinated Tax secretion from infected lymphocytes of HAM/TSP patients and HTLV-1 carriers. Furthermore, CRT levels in culture medium are associated with Tax extracellular levels, which would point to a common secretion mechanism as shown in Fig. 4.

CRT, a classical ER resident protein, could participate in the destination of Tax protein to the canonical secretory pathway.³⁰ This can be explained by at least two putative secretory signals in Tax, allowing the secretion of both Tax and CRT as we have observed.^{11,13} In the current study, CRT secretion in culture medium of PBMCs supports the growing evidence that CRT is not confined in the ER as initially

described by Michalak in 1992.^{41,42} CRT has been found in cytoplasm, nucleus, Golgi, plasma membrane, and even extracellularly in many cell types and tissues, despite of the C-terminal ER localization signal (KDEL) and the lack of secretory signals.^{41,42} In Hep2 cells, Tax leads to a redistribution of CRT from the nucleus to the cytoplasm.³¹ Some authors suggest a cleavage of the ER retention signal or interaction with another protein masking the KDEL sequence.⁴¹ Tax interaction with CRT in HTLV-1-infected lymphocytes might be involved in ER retention signal masking. Moreover, Tax interaction with various proteins might form complexes involved in the regulated secretion pathway. Tax could act as a carrier protein for CRT trafficking via secretion vesicles in HTLV-1-infected lymphocytes.¹³ Thus, Tax and CRT could be cosecreted, which would imply a new mechanism of CRT and Tax secretion. Our results show a positive correlation between Tax and the 56-kDa CRT levels in PBMC culture medium of HAM/TSP patients and also coincide with the similar secretion of both proteins.

CRT is widely accepted as a multifunctional protein and current information describes some extracellular effects of CRT, such as promoting wound healing, cell survival, and participating in immune responses against cancer cells.^{41,42,43} Thus, CRT in extracellular environments favors human health. HTLV-1 has evolved along with humans since ancient times and has a variety of immunological escape and host survival mechanisms.^{44,45} Consequently, the higher levels of secreted CRT would have beneficial effects on HTLV-1-infected subjects, providing survival mechanisms that would counteract the deleterious effects of Tax.

Our studies on Tax posttranslational modifications in the HTLV-1-infected MT-2 cell line discard the modifications with ubiquitin-like proteins; however, Tax was detected as a fusion protein with gp21—a membrane HTLV-1 glycoprotein.^{34,35,46} Previous studies showed an interaction between Tax and CRT near the nuclear membrane of the BHK-21 cell line cotransfected with *tax* and *crt* genes.³⁰ These authors identified CRT as a nuclear export receptor for Tax, suggesting a control checkpoint for nuclear export, including an additional complexity level to the Tax intracellular location. We found this interaction in MT-2 cells of the cytoplasmic region, probably in ER structures where CRT preferentially locates and interacts with different proteins during folding and quality control of secreted proteins.⁴⁷ In these infected cells, we demonstrated that the Tax–CRT interaction occurred by immune colocalization and coimmunoprecipitation, similar to that reported in transfected cells with both *tax* and *crt* genes.³⁰

The steady state of K63-linked ubiquitination of Tax seems to depend on Ubc13, an E2 ubiquitin-conjugating enzyme, while the ubiquitin-specific peptidase USP20 would act as a ubiquitin-editing enzyme.^{24,26,48,49} On the other hand, this peptidase was detected in Tax transfected HEK293T cells, with reduced activity, as well as in several HTLV-1 transformed cells such as MT-1, MT-2, MT-4, and AT-2.⁴⁸ We detected a ubiquitinated Tax form only in infected human PBMCs, probably indicating that peptidase might be less active or absent in these cells.

In conclusion, our study reveals differences between the Tax secreted from HTLV-1-infected T-lymphocytes—which becomes ubiquitinated—and that from MT-2 cells. Tax secretion

occurs via the classical ER–Golgi pathway, where CRT may be involved in a cosecretion mechanism due to the extracellular interaction of Tax and CRT. The similar effects of the 40-kDa Tax present in supernatants of MT-2 cells¹⁸ and the 57-kDa Tax form in HAM/TSP PBMC supernatants indicate the ubiquitin-independent neurotoxic effect of this secretable viral protein.

Sequence Data

Accession numbers: HTLV-1 Tax, BAB18052; HTLV-1 envelope glycoprotein, AAU04944.

Acknowledgments

We thank Professor Claudio Telha for his valuable input when reviewing the manuscript. We are grateful to Fondecyt, which supported this study (Grant Fondecyt 108-0396), to Project Mecesus UCH 0115, which allowed the use of the Mass Spectrometry Instrument, to the doctoral thesis supported by CONICYT no. 24090150, and to the master thesis supported by CONICYT no. 22110639. We also thank the NIH AIDS Reagent Program for the HTLV-1 Tax hybridoma.

Author Disclosure Statement

No competing financial interests exist.

References

- Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, and Gallo RC: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc Natl Acad Sci USA* 1980;77:7415–7419.
- Yoshida M, Miyoshi I, and Hinuma Y: Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. *Proc Natl Acad Sci USA* 1982;79:2031–2035.
- Cartier L, Cea JG, Vergara C, Araya F, and Born P: Clinical and neuropathological study of six patients with spastic paraparesis associated with HTLV-1: An axomyelinic degeneration of the central nervous system. *J Neuropathol Exp Neurol* 1997;56:403–413.
- Cartier L, Vergara C, and Valenzuela MA: Immunohistochemistry of degenerative changes in the central nervous system in spastic paraparesis associated to human T lymphotropic virus type I (HTLV-1). *Rev Med Chil* 2007;135:1139–1146.
- Yamano Y, Takenouchi N, Li H, Tomaru U, Yao K, Grant C, Maric D, and Jacobson S: Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-1-associated neuroimmunological disease. *J Clin Invest* 2005;115:1361–1368.
- Toulza F, Heaps A, Tanaka Y, Taylor GP, and Bangham CR: High frequency of CD4+Foxp3+ cells in HTLV-1 infection: Inverse correlation with HTLV-1-specific CTL response. *Blood* 2008;111:5047–5053.
- Alberti C, Cartier L, Valenzuela MA, Puente J, Tanaka Y, and Ramirez E: Molecular and clinical effects of beta-methasone in human T-cell lymphotropic virus type-1-associated myelopathy/tropical spastic paraparesis patients. *J Med Virol* 2011;83:1641–1649.


8. Afonso PV, Ozden S, Cumont MC, *et al.*: Alteration of blood–brain barrier integrity by retroviral infection. *PLoS Pathog* 2008;4:e1000205.
9. Grant C, Barmak K, Alefantis T, Yao J, Jacobson S, and Wigdahl B: Human T cell leukemia virus type I and neurologic disease: Events in bone marrow, peripheral blood, and central nervous system during normal immune surveillance and neuroinflammation. *Cell Physiol* 2002;190:133–159.
10. Ramírez E, Fernández J, Cartier L, Villota C, and Ríos M: Defective human T-cell lymphotropic virus type I (HTLV-1) provirus in seronegative tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM) patients. *Virus Res* 2003;91:231–239.
11. Alefantis T, Mostoller K, Jain P, Harhaj E, Grant C, and Wigdahl B: Secretion of the human T cell leukemia virus type I transactivator protein tax. *J Biol Chem* 2005;280:17353–17362.
12. Alefantis T, Jain P, Ahuja J, Mostoller K, and Wigdahl B: HTLV-1 Tax nucleocytoplasmic shuttling, interaction with the secretory pathway, extracellular signaling, and implications for neurologic disease. *J Biomed Sci* 2005;12:961–974.
13. Jain P, Mostoller K, Flaig KE, *et al.*: Identification of human T cell leukemia virus type 1 tax amino acid signals and cellular factors involved in secretion of the viral oncoprotein. *J Biol Chem* 2007;282:34581–34593.
14. Boxus M, Twizere JC, Legros S, Dewulf JF, Kettmann R, and Willems L: The HTLV-1 Tax interactome. *Retrovirology* 2008;5:76.
15. Lodewick J, Lamsoul I, Polania A, *et al.*: Acetylation of the human T-cell leukemia virus type 1 Tax oncoprotein by p300 promotes activation of the NF-kappaB pathway. *Virology* 2009;386:68–78.
16. Lodewick J, Lamsoul I, and Bex F: Move or die: The fate of the Tax oncoprotein of HTLV-1. *Viruses* 2011;3:829–857.
17. Cartier L and Ramírez E: Presence of HTLV-1 Tax protein in cerebrospinal fluid from HAM/TSP patients. *Arch Virol* 2005;150:743–753.
18. Maldonado H, Ramirez E, Utreras E, *et al.*: Inhibition of cyclin-dependent kinase 5 but not of glycogen synthase kinase 3- β prevents neurite retraction and tau hyperphosphorylation caused by secretable products of human T-cell leukemia virus type I-infected lymphocytes. *J Neurosci Res* 2011;89:1489–1498.
19. Durkin S, Ward M, Fryrear K, and Semmes O: Site-specific phosphorylation differentiates active from inactive forms of the human T-cell leukemia virus type 1 Tax oncoprotein. *J Biol Chem* 2006;281:31705–31712.
20. Peloponese JM Jr, Iha H, Yedavalli VR, *et al.*: Ubiquitination of human T-cell leukemia virus type 1 Tax modulates its activity. *J Virol* 2004;78:11686–11695.
21. Lamsoul I, Lodewick J, Lebrun S, *et al.*: Exclusive ubiquitination and SUMOylation on overlapping lysine residues mediate NF-kB activation by the human T-cell leukemia virus Tax oncoprotein. *Mol Cell Biol* 2005;25:10391–10406.
22. Nasr R, Chiari E, El-Sabban M, *et al.*: Tax ubiquitination and SUMOylation control critical cytoplasmic and nuclear steps of NF-kB activation. *Blood* 2006;107:4021–4029.
23. Kfoury Y, Nasr R, Favre-Bonvin A, *et al.*: Ubiquitylated Tax targets and binds the IKK signalosome at the centrosome. *Oncogene* 2008;27:1665–1676.
24. Kfoury Y, Nasr R, Journo C, Mahieux R, Pique C, and Bazarbachi A: The multifaceted oncoprotein Tax: Subcellular localization, posttranslational modifications, and NF-kB activation. *Adv Cancer Res* 2012;113:85–120.
25. Jeang KT: Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: Cellular signaling through NF-kappa B. *Cytokine Growth Factor Rev* 2001;12:207–217.
26. Journo C, Bonnet A, Favre-Bonvin A, *et al.*: HTLV-2 Tax-mediated NF-kB activation involves a mechanism independent of Tax conjugation to ubiquitin and SUMO. *J Virol* 2013;87:1123–1136.
27. Bonnet A, Randrianarison-Huetz V, Nzounza P, *et al.*: Low nuclear body formation and tax SUMOylation do not prevent NF-kappaB promoter activation. *Retrovirology* 2012;9:77.
28. Alefantis T, Barmak K, Harhaj EW, Grant C, and Wigdahl B: Characterization of a nuclear export signal within the human T cell leukemia virus type I transactivator protein Tax. *J Biol Chem* 2003;278:21814–21822.
29. Tsuji T, Sheehy N, Gautier VW, Hayakawa H, Sawa H, and Hall WW: The nuclear import of the human T lymphotropic virus type I (HTLV-1) tax protein is carrier- and energy-independent. *J Biol Chem* 2007;282:13875–13883.
30. Alefantis T, Flaig KE, Wigdahl B, and Jain P: Interaction of HTLV-1 Tax protein with calreticulin: Implications for Tax nuclear export and secretion. *Biomed Pharmacother* 2007;61:194–200.
31. Avesani F, Romanelli MG, Turci M, *et al.*: Association of HTLV Tax proteins with TAK1-binding protein 2 and RelA in calreticulin-containing cytoplasmic structures participates in Tax-mediated NF-kB activation. *Virology* 2010;408:39–48.
32. Ramírez E, Cartier L, and Flores R: In vitro cytoskeleton changes of mouse neurons induced by purified HTLV-1, and PBMC from HAM/TSP patients and HTLV-1 carriers. *Arch Virol* 2004;149:2307–2317.
33. Hanon E, Hall S, Taylor GP, *et al.*: Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-1) is prevented by cytotoxic T lymphocytes. *Blood* 2000;95:1386–1392.
34. Miwa M, Shimotohno K, Hoshino H, Fujino M, and Sugimura T: Detection of pX proteins in human T-cell leukemia virus (HTLV)-infected cells by using antibody against peptide deduced from sequences of X-IV DNA of HTLV-1 and Xc DNA of HTLV-II proviruses. *Gann* 1984;75:752–755.
35. Takeuchi K, Kobayashi N, Nam SH, Yamamoto N, and Hatanaka M: Molecular cloning of cDNA encoding gp68 of adult T-cell leukaemia-associated antigen: Evidence for expression of the pX IV region of human T-cell leukaemia virus. *J Gen Virol* 1985;66:1825–1829.
36. Journo C, Douceron E, and Mahieux R: HTLV-1 gene regulation: Because size matters, transcription is not enough. *Future Microbiol* 2009;4:425–440.
37. Nejmeddine M, Barnard A, Tanaka Y, Taylor G, and Bangham C: Human T lymphotropic virus type 1, Tax protein triggers microtubule reorientation in the virological synapse. *J Biol Chem* 2005;280:29653–29660.
38. Irish BP, Khan ZK, Jain P, *et al.*: Molecular mechanisms of neurodegenerative diseases induced by human retroviruses: A review. *Am J Infect Dis* 2009;5:231–258.
39. Lepoutre V, Jain P, Quann K, Wigdahl B, and Khan KK: Role of resident CNS cell populations in HTLV-1-associated

- neuroinflammatory disease. *Front Biosci* 2009;14:1152–1168.
40. Xiao G: NF-kappaB activation: Tax sumoylation is out, but what about Tax ubiquitination? *Retrovirology* 2012;9:78.
 41. Gold LI, Eggleton P, Sweetwyne MT, *et al.*: Calreticulin: non-endoplasmic reticulum functions in physiology and disease. *FASEB J* 2010;24:665–683.
 42. Wang WA, Groenendyk J, and Michalak M: Calreticulin signaling in health and disease. *Int J Biochem Cell Biol* 2012;44:842–846.
 43. Ferreira V, Molina MC, Schwaeble W, Lemus D, and Ferreira A: Does *Trypanosoma cruzi* calreticulin modulate the complement system and angiogenesis? *Trends Parasitol* 2005;21:169–174.
 44. Li HC, Fujiyoshi T, Lou H, *et al.*: The presence of ancient human T-cell lymphotropic virus type I provirus DNA in an Andean mummy. *Nat Med* 1999;5:1428–1432.
 45. Gallo RC: Human retroviruses after 20 years: A perspective from the past and prospects for their future control. *Immunol Rev* 2002;185:236–265.
 46. Sugamura K, Fujii M, Ueda S, and Hinuma Y: Identification of a glycoprotein, gp21, of adult T cell leukemia virus by monoclonal antibody. *J Immunol* 1984;132:3180–3184.
 47. Michalak M, Corbett EF, Mesaeli N, Nakamura K, and Opas M: Calreticulin: One protein, one gene, many functions. *Biochem J* 1999;344(Pt 2):281–292.
 48. Yasunaga J, Lin FC, Lu X, and Jeang KT: Ubiquitin-specific peptidase 20 targets TRAF6 and human T cell leukemia virus type 1 tax to negatively regulate NF-kappaB signaling. *J Virol* 2011;85:6212–6219.
 49. Shembade N, Harhaj NS, Yamamoto M, Akira S, and Harhaj EW: The human T-cell leukemia virus type 1 Tax oncoprotein requires the ubiquitin-conjugating enzyme Ubc13 for NF-kappaB activation. *J Virol* 2007;81:13735–13742.

Address correspondence to:

Maria Antonieta Valenzuela
Departamento de Bioquímica y Biología Molecular
Facultad de Ciencias Químicas y Farmacéuticas
Universidad de Chile
Sergio Livingstone 1007
Santiago 233
Chile

E-mail: mavalenz@uchile.cl



RESEARCH

Open Access

Natural OX40L expressed on human T cell leukemia virus type-I-immortalized T cell lines interferes with infection of activated peripheral blood mononuclear cells by CCR5-utilizing human immunodeficiency virus

Daigo Kasahara¹, Azusa Takara¹, Yoshiaki Takahashi¹, Akira Kodama¹, Reiko Tanaka¹, Aftab A Ansari² and Yuetsu Tanaka^{1*}

Abstract

Background: OX40 ligand (OX40L) co-stimulates and differentiates T cells via ligation of OX40 that is transiently induced on T cells upon activation, resulting in prolonged T cell survival and enhanced cytokine production by T cells. This view has led to the targeting of OX40 as a strategy to boost antigen specific T cells in the context of vaccination. In addition, the ligation of OX40 has also been shown to inhibit infection by CCR5-utilizing (R5) but not CXCR4-utilizing (X4) human immunodeficiency virus type-1 (HIV-1) via enhancement of production of CCR5-binding β -chemokines. It was reasoned that human T cell leukemia virus type-I (HTLV-1) immortalized T cell lines that express high levels of OX40L could serve as a unique source of physiologically functional OX40L. The fact that HTLV-1⁺ T cell lines simultaneously also express high levels of OX40 suggested a potential limitation.

Results: Results of our studies showed that HTLV-1⁺ T cell lines bound exogenous OX40 but not OX40L, indicating that HTLV-1⁺ T cell lines express an active form of OX40L but an inactive form of OX40. Anti-OX40 non-blocking monoclonal antibody (mAb), but not blocking mAb, stained HTLV-1⁺ T cell lines, suggesting that the OX40 might be saturated with endogenous OX40L. Functionality of the OX40L was confirmed by the fact that a paraformaldehyde (PFA)-fixed HTLV-1⁺ T cell lines inhibited the infection of autologous activated peripheral blood mononuclear cells (PBMCs) with R5 HIV-1 which was reversed by either anti-OX40L blocking mAb or a mixture of neutralizing mAbs against CCR5-binding β -chemokines.

Conclusions: Altogether, these results demonstrated that autologous T cell lines immortalized by HTLV-1 can be utilized as a conventional source of physiologically functional OX40L.

Background

OX40 ligand (OX40L, CD252) belonging to the tumor necrosis factor (TNF) superfamily is a co-stimulatory molecule [1,2] that was first described by our laboratory as gp34 that is constitutively expressed at high levels on the surface of human T cell leukemia virus type-I (HTLV-1)-immortalized T cell lines [3,4]. It is now clear that OX40L can be induced on a wide variety of human hematopoietic

cell lineages including antigen presenting cells (APCs) such as dendritic cells (DCs) [5] and B cells [6], natural killer (NK) cells [7], mast cells [8], endothelial cells [9] and T cells [10,11]. OX40 (CD134), a member of the TNF receptor (TNFR) superfamily that is rapidly induced predominantly on T cells upon cell activation is the cognate receptor for OX40L [12-14]. Interaction of OX40 on T cells with OX40L on APCs generates a variety of biological changes that include enhanced production of cytokines by T cells, Th2 cell differentiation, prolonged T cell survival, activation of B cells and DCs, to name a few

* Correspondence: yuetsu@s4.dion.ne.jp

¹Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan

Full list of author information is available at the end of the article

[1,12,15]. OX40L is naturally expressed on the cell surface as a trimeric protein that binds to three copies of monomeric OX40 within close proximity [16]. Such close interactions between OX40/OX40L promotes tight cell to cell adhesion facilitating T cell-DC communication and skin infiltration of OX40⁺ leukemic T cells in adult T cell leukemia (ATL) [17].

It has been proposed that the targeting of OX40 on activated T cells by OX40L or with the use of anti-OX40 agonistic antibodies may provide a strategy for the selective expansion of the limited frequencies of antigen specific T cells that are normally induced during vaccination and thereby achieve more effective immune responses [18-20]. Another immunological role of OX40L-OX40 interaction that we have previously documented includes the ability of OX40L in either soluble or membrane-bound form to effectively inhibit the infection of activated PBMCs with R5 HIV-1 *in vitro* [21]. This inhibition was shown to be mediated via the enhanced production of the CCR5-binding β -chemokines that include RANTES, MIP-1 α and MIP-1 β , followed by the down-modulation of cell surface CCR5 expression. These findings brought into focus the potential use of OX40L as a therapeutic tool and prompted us to investigate methodologies that would provide a convenient source for biologically active OX40L. One such source of OX40L was reasoned to be HTLV-1⁺ T cell lines that unlike normal activated T cells or non-T cells have been shown to express both OX40L and OX40 on the cell surface at a single cell level due to the action of the HTLV-1-encoded oncogenic protein Tax [4,22]. Tax, in addition, also induces the expression of 4-1BB and its cognate ligand both of which belong to the TNF/TNFR family [23]. Selective induction of these ligand/receptor pairs has been implicated in the survival of HTLV-1-infected cells.

Studies were therefore carried out in efforts to examine whether OX40L and OX40 were expressed in a biologically active form by HTLV-1⁺ T cell lines. We report herein for the first time that HTLV-1⁺ T cell lines express a biologically active form of OX40L while the OX40 molecule appears biologically inactive or masked. The OX40L expressed by HTLV-1⁺ T cell lines was capable of inhibiting R5 HIV-1 infection of activated PBMCs via production of CCR5-binding β -chemokines. These findings suggest that autologous HTLV-1-immortalized T cell lines can be utilized as a readily available convenient source of natural OX40L in large quantities for various immunological studies.

Results

HTLV-1-immortalized T cell lines express active OX40L together with inactive OX40


In order to determine whether OX40L and OX40 co-expressed on the cell surface of HTLV-1⁺ T cell lines were biologically active, we examined their capacities to bind

biotinylated rec-OX40 and rec-OX40L, respectively. The finding that rec-OX40 and rec-OX40L bound specifically to the OX40L-transfected CEM cells (CEM/OX40L) and the OX40-transfected CEM/OX40 cells, respectively, demonstrated the specificity of the assay being utilized (Figure 1). Interestingly, although the standard HTLV-1⁺ T cell line (MT-2) was stained double positive with anti-OX40L (clone 5A8) and anti-OX40 (clone B-7B5) mAbs, they bound only rec-OX40 but not rec-OX40L. This finding indicated that while OX40L was expressed in an active form on MT-2 cells, the OX40 was likely to be expressed in an inactive form. Similar results were obtained by the testing of a number of additional HTLV-1⁺ T cell lines, including T cell lines spontaneously established from a HTLV-1-infected patient with adult T cell leukemia (ILT-H2) and a HTLV-1-associated myelopathy (HAM/TSP) patient (ILT-M1), and various *in vitro*-HTLV-1-immortalized CD4⁺ or CD8⁺ T cell lines from different healthy donors (such as YT/cM1, RT/cH2 cells) (Figure 1). Thus, these results suggest that on the cell surface of the HTLV-1⁺ T cell lines only OX40L, but not OX40, is capable of binding its respective ligand.

Characterization of OX40 on HTLV-1⁺ T cells

A series of studies were subsequently conducted in efforts to identify the potential reason(s) for the failure of HTLV-1⁺ T cell lines to bind rec-OX40L. Western Blot analysis of OX40 expressed by HTLV-1⁺ T cell line was first carried out to determine whether the OX40 expressed by these cells was truncated. Cell lysates prepared from surface biotinylated *in vitro* activated PBMCs and the OX40 transfected CEM cell line (CEM/OX40) were analyzed in parallel with the HTLV-1⁺ T cell line MT-2 using standard Western Blot techniques. Results of these studies displayed in Figure 2 showed that there were no detectable differences in the molecular weight of the glycosylated authentic OX40 (50 kDa) among these three samples. The 35 kDa band corresponding to the non-glycosylated form of OX40 was apparent in CEM/OX40 cells and activated PBMCs, but it was faint in MT-2 cells. These data indicated that there was no detectable deletion or modification in the glycosylated OX40 molecules expressed by the HTLV-1⁺ T cell lines.

To further probe for the molecular basis for the inability of the OX40 expressed by the HTLV-1⁺ T cell lines to bind rec-OX40L, we utilized an additional anti-OX40 specific mAb (W4-54 mAb) along with B-7B5 mAb. While the clone W4-54 anti-OX40 mAb inhibited the binding of OX40 and OX40L, the clone B-7B5 failed to show any detectable inhibition (Additional file 1: Figure S1). These two mAbs are reasoned to react against conformational epitopes since they failed to bind any overlapping 15-mer peptides spanning the entire OX40 protein (data not shown). As shown in Figure 3(A), control mock treated CEM/




OX40 and activated PBMCs, as expected, both stained dual-positive with the B-7B5 mAb and W4-54 mAbs. These data show that the comparative staining with B-7B5 and W4-54 mAbs can be potentially utilized to distinguish between non-ligated versus OX40L ligated forms of OX40. Figure 3(B) shows that although B-7B5 mAb stained HTLV-1⁺ T cell lines at high levels, little or no staining was noted with the use of the W4-54 mAb. In contrast, results of a WB analysis showed that the W4-54 mAb readily reacts to the p50 of the OX40 molecule in lysates of the HTLV-1⁺ T cell line, YT/cM1 (Additional file 2: Figure S2). These results suggest that the OX40L binding site of OX40 expressed by the HTLV-1⁺ T cell lines was altered, most probably due to pre-occupation with endogenous OX40L. To confirm this possibility, we explored the presence of OX40-OX40L complexes expressed by HTLV-1⁺ T cell lines using our in-house ELISA. Cell lysates of the ATL-derived HTLV-1⁺ T cell line (ILT-H2) were first captured with the use of immobilized anti-OX40L (clone HD-1) or anti-OX40 (clone B-7B5) mAb, respectively. The levels of captured antigens were assayed with the use of HRP-labeled anti-OX40 mAb or anti-OX40L mAb. Although it is reasonable to assume that the natural interaction between OX40 and OX40L on

the living cell surface may be dissociated by the detergent treatment, as shown in Figure 4, low but significant levels of OX40-OX40L complex were still detectable in the cell lysates.

Functional OX40L expressed by HTLV-1⁺ T cell lines

To confirm that the OX40L expressed on the HTLV-1⁺ T cell lines is biologically functional, we performed co-culture experiments using the experimental *in vitro* infection of autologous activated PBMCs with HIV-1 as a read out. PBMCs activated with anti-CD3/anti-CD28 mAbs for 24 hours were washed and infected with either R5 HIV-1_{JR-FL} or X4 HIV-1_{NL4-3} at a low m.o.i., and then co-cultured with paraformaldehyde (PFA)-fixed autologous HTLV-1⁺ T cell line in the presence or absence of anti-OX40L mAb or a mixture of the three CCR5-binding chemokine-blocking mAbs (anti-RANTES, anti-MIP-1 α and anti-MIP-1 β). The reasons why we utilized autologous PFA-fixed HTLV-1⁺ T cell lines were to avoid any allogeneic stimuli and minimize the secretion of any anti-HIV-1 factors by the HTLV-1⁺ T cell lines. As shown in Figure 5, the frequencies of HIV-1 p24⁺ T cells in the cultures were reduced by co-culture with not only autologous HTLV-1⁺ T cell line but also with the



addition of soluble rec-OX40L. This inhibition was mediated by OX40L-OX40 interaction since the addition of the anti-OX40L blocking mAb (clone 5A8) and/or the addition of a mixture of the anti- β -chemokine mAbs reversed the level of reduction. It is worthy to note that, similar to data we have previously reported with the use of recombinant OX40L [21], X4 HIV-1 infection was not influenced by co-cultivation with PFA-fixed HTLV-1⁺ T cell line, suggesting the CCR5-specificity of this antiviral effect.

Finally, we compared the potential of membrane bound OX40L of the fixed HTLV-1⁺ T cell lines with that of soluble rec-OX40L to inhibit R5 HIV-1 infection by the quantitation of p24 production in the culture supernatants. As shown in Figure 6, whereas the inhibitory effect of the rec-OX40L reached a plateau at levels > 1.25 μ g/ml, the autologous HTLV-1⁺ T cell line could inhibit more effectively at even an HTLV-1⁺ T cell to PBMCs ratio as low as 0.3. The maximum inhibition reached with rec-OX40 was around 65% of the maximum inhibition reached with HTLV-1⁺ T cell line, with similar IC₅₀. Altogether, these data demonstrate that indeed, the OX40L expressed by HTLV-1⁺ T cell lines is biologically active.

Discussion

In the present study, we revealed that the cell surface expressed OX40L on T cell lines immortalized by HTLV-1

is biologically active in concert with the co-expression of an inactive form of OX40. As far as we know, this is the first study to report the polarized “OX40L-active/OX40 inactive” expression by HTLV-1⁺ T cell lines. The expression of active forms of OX40L is not unique to HTLV-1⁺ T cell lines, since similar conditions have also been observed in normal T cells when they are activated under mild DNA damaging conditions or cultured for long-term in IL-2 containing media with periodic stimulation [11,24]. However, compared to these normal T cells, HTLV-1⁺ T cell lines are immortal and thus can provide unlimited amounts of OX40L.

The precise mechanism for the inability of OX40 on HTLV-1⁺ T cell lines to bind OX40L remains to be clearly defined. Based on our previous paper showing that functional OX40L can be transferred to OX40 intercellularly [25], we hypothesize that the cell surface OX40 may be saturated with endogenously produced OX40L in *cis* and/or *trans* mode. Indeed, the WB analysis showed that the OX40-OX40L blocking mAb W4-54 that did not stain living HTLV-1⁺ T cells reacted to the p50 OX40 molecule (Additional file 2: Figures S2 and Additional file 3: Figures S3). In accordance with this assumption, we demonstrated the presence of OX40-OX40L complexes in lysates of HTLV-1⁺ T cell lines by ELISA (Figure 4). It remains unclear why there were significant amounts of OX40L-free OX40 molecules in the lysates from HTLV-1⁺ T cells as determined by ELISA. It will be highly likely that the detergent treatment dissociates the OX40 and OX40L complex due to perturbation of cytoplasmic membrane structure including lipid rafts on which OX40 is supposed to reside in association with the other TNFR member such as 4-1BB [26,27]. In addition, our preliminary data that supports the OX40 saturation hypothesis includes the finding using the HUT 102 cell line that is another HTLV-1⁺ T cell line from which the original OX40 gene was cloned [13]. This HUT102 cell line stained with both B-7B5 and W4-54 mAbs, but not with anti-OX40L (5A8 mAb), and was able to bind recombinant OX40L but not OX40 (Additional file 3: Figure S3). Although it is not clear why HUT102 cell line was positive for Tax antigen but negative for OX40L expression, these data clearly showed that in the absence of OX40L, functional OX40 can be expressed on the cell surface. It will be of interest to examine whether the inactive form of the OX40 can be converted to an active form after silencing the expression of OX40L in HTLV-1⁺ T cell lines. Such studies are currently in progress.

On the basis of the present and previous results on OX40L [21], it can be hypothesized that OX40L may have a therapeutic and prophylactic potential against R5 HIV-1 infection. However, at present, purified biologically active forms of human OX40L protein in large quantities is not available. The alternative is to utilize